

University of California, San Francisco
CURRICULUM VITAE

Name: Michael Thomas Tetzlaff

Position: Professor
Pathology
School of Medicine

Address: University of California, San Francisco
Email: Michael.tetzlaff@ucsf.edu

EDUCATION

-	Degree-Granting Education			
1989 - 1993	The University of Texas at Austin	BA	Plan II, Pre-Med	
1997 - 2003	Baylor College of Medicine, Houston, TX	PhD	Molecular and Human Genetics	Dr. Stephen J. Elledge
1995 - 2005	Baylor College of Medicine, Houston, TX	MD		
-	Postgraduate Training			
1993 - 1995	Max Planck Institute for Biophysical Chemistry and Georg August Georg August University of Göttingen, Goettingen, Germany		Developmental Biology and Genetics	Dr. Herbert Jaeckle
2005 - 2009	Hospital of the University of Pennsylvania, Department of Pathology and Laboratory Medicine, Philadelphia, PA	Resident	Anatomic Pathology	
2008 - 2008	Hospital of the University of Pennsylvania, Department of Pathology and Laboratory Medicine, Philadelphia, PA	Chief Resident	Anatomic Pathology	
2009 - 2010	Hospital of the University of Pennsylvania, Department of Dermatology, Philadelphia, PA	Fellow	Dermatopathology	
-	CREDENTIALS			
-	Board Certification			

2009 - 2019	American Board of Pathology 09-053	Anatomic Pathology
2010 - 2020	American Board of Pathology S-10-224	Dermatopathology

LICENSES, CERTIFICATION

Active

8/2010	Medical License, TX, N6711
04/2020	California Physicians and Surgeons License, C 168623

Inactive

2010	Medical License, Pennsylvania, MD436205
------	---

PRINCIPAL POSITIONS HELD

08/2010 - 07/2016	The University of Texas MD Anderson Cancer Center, Houston, Texas	Assistant Professor, Tenure Track	Pathology
08/2010 - 07/2016	The University of Texas MD Anderson Cancer Center, Houston, Texas	Assistant Professor, Tenure Track	Translational and Molecular Pathology
08/2016 - 2020	The University of Texas MD Anderson Cancer Center, Houston, Texas	Associate Professor, Tenure Track	Pathology
08/2016 - -2020	The University of Texas MD Anderson Cancer Center, Houston, Texas	Associate Professor, Tenure Track	Translational and Molecular Pathology
09/2018 - -2020	Digital Imaging Laboratory, Department of Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX,	Medical Director	Pathology
2020	University of California, San Francisco	Professor, Dermatopathology	

OTHER POSITIONS HELD CONCURRENTLY

08/2015 - present	Translational Research Program, The Alliance for Clinical Trials, Chicago, IL	Executive Officer
2014 - 2014	Galderma, Zurich Switzerland	Advisory Board
2015 - 2018	Seattle Genetics, Seattle, WA	Consultant/Advisory Board
2015 - present	Myriad Genetics, Salt Lake City, Utah	Advisory Board
2018 - 2019	Novartis, LLC	Advisory Board

2019 - 2019	Nanostring, LLC	Consultant/Advisory Board	
11/2018 - present	National Cancer Institute (NCI) Cancer Immune Monitoring and Analysis Centers & Cancer Immunologic Data Commons (CIMAC-CIDC), Multiplex Immunofluorescence Working Group.	Co-Chairman	
01/2019 - present	Southwestern Oncology Group, Melanoma Committee, Pathology Chair	Pathology Chair	
11/2019 - present	Translational and Molecular Pathology Immune Profiling Laboratory (TMP-IL), Department of Translational and Molecular Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX	Co-Director	Translational and Molecular Pathology

HONORS AND AWARDS

1993	Deutsche Akademische Auschtauschdienst (DAAD) Fellowship, Max Planck Institute for Biophysical Chemistry, Goettingen Germany	Deutsche Akademische Auschtauschdienst (DAAD)	
1994	Division of Developmental Biology, Student Fellowship, Max Planck Institute for Biophysical Chemistry Student Fellowship	Max Planck Institute for Biophysical Chemistry, Goettingen Germany	
1993	Phi Beta Kappa	The University of Texas at Austin	
1995	Hudson Scholar	Baylor College of Medicine Houston, Texas	
1995	Presidential Scholar	Baylor College of Medicine Houston, Texas	
1998	Ilmar Kuisk Outstanding Senior Teaching Assistant Award, Cell Biology and Histology Course	Baylor College of Medicine Houston, Texas	
1998	John J. Trentin Award for Academic Excellence in Graduate School, Baylor College of Medicine	Baylor College of Medicine Houston, Texas	
1999	Ilmar Kuisk Outstanding Senior Teaching Assistant Award, Cell Biology and Histology Course	Baylor College of Medicine Houston, Texas	

2003	Outstanding Platform Presentation, Medical Scientist Training Program Annual Retreat	Baylor College of Medicine Houston, Texas
2004	Resident's Choice Award for Outstanding Medical Student, Department of Pathology	Baylor College of Medicine Houston, Texas
2005	Richard R. Dickason Outstanding Physician Scientist Award	Medical Scientist Training Program (MSTP) Baylor College of Medicine Houston, Texas
2007	Leonard R. Jarrett Research Symposium Resident Platform Presentation	Hospital for the University of Pennsylvania, Department of Pathology and Laboratory Medicine
2007	Ronni A. Ladoto Residence Excellence in Teaching Award	Hospital for the University of Pennsylvania, Department of Pathology and Laboratory Medicine
2011	Stelwagon Award, Honorable Mention, Dermatology	The College of Physicians of Philadelphia
2019	Shirley Stein Scientific Endowed Research Award	The University of Texas MD Anderson Cancer Center, Houston, Texas

PROFESSIONAL ACTIVITIES

MEMBERSHIPS

- 2006 - present The United States and Canadian Academy of Pathology, Member
- 2006 - 2008 The United States and Canadian Academy of Pathology, Education Committee
- 2008 - present American Society of Dermatopathology, Member
- 2009 - 2010 Philadelphia Pathology Society
- 2020 - present Houston Society of Clinical Pathologists
- 2010 - present American Academy of Dermatology, Member
- 2010 - present American Society of Clinical Pathology, Member
- 2013 - present College of American Pathologists, Member
- 2013 - present American Society of Clinical Pathology, Member
- 2015 - present The Alliance for Clinical Trials

2018 - present Southwestern Oncology Cooperative Group (SWOG), Melanoma Committee

SERVICE TO PROFESSIONAL ORGANIZATIONS

2006 - 2008	Education Committee, United States and Canadian Academy of Pathology	Resident member
2011 - 2014	Annual Meeting Abstract Review Committee, United States and Canadian Academy of Pathology	Member
2015 - 2016	American Society of Dermatopathology, Maintenance of Certification Committee	Member
2015 - present	American Society of Clinical Pathology, Abstract Review Committee	Member
2015 - 2018	American Society of Clinical Pathology, Annual Meeting Scientific Program Committee,	Member
2016 - 2017	American Society of Dermatopathology, Virtual Slide Library Committee	Member
2016 - 2018	American Society of Dermatopathology, Maintenance of Certification Committee	Vice Chairman
2016 - present	The Alliance for Clinical Trials, Conflict of Interest Committee	Member,
2017 - present	American Society of Dermatopathology, Peer Review Committee	Member
2017 - present	American Society of Dermatopathology, Abstract Review Committee	Member
2018 - present	American Society of Dermatopathology, Maintenance of Certification Committee	Chairman
2020 - present	United States and Canadian Academy of Pathology, Dermatopathology Evening Slide Symposium	Organizer

SERVICE TO PROFESSIONAL PUBLICATIONS

2019 - 2020	Editor, Surgical Pathology Clinics
2017 - present	Associate Editor, Human Pathology
2018 - present	Associate Editor, Journal of Cutaneous Pathology
2019 - present	Associate Editor, Modern Pathology
2011 - 2020	Editorial Review Board, Frontiers
2015 - 2019	Editorial Review Board, American Journal of Clinical Pathology
2015 - present	Editorial Review Board, Applied Immunohistochemistry and Molecular Morphology

2016 - present Editorial Review Board, Human Pathology
2017 - present Editorial Review Board, Journal of Cutaneous Pathology
2107 - present Editorial Review Board, Laboratory Investigation
2019 - present Editorial Review Board, American Journal of Surgical Pathology
2010 - 2017 Ad-hoc reviewer, Journal of Cutaneous Pathology
2010 - present Ad-hoc reviewer, International Journal of Cancer
2011 - present Ad-hoc reviewer, Archives of Pathology
2012 - present Ad-hoc reviewer, Archives of Dermatology
2012 - present Ad-hoc reviewer, Endocrine Pathology
2013 - present Ad-hoc reviewer, Archives of Dermatological Research
2013 - present Ad-hoc reviewer, Head and Neck
2014 - 2019 Ad-hoc reviewer, Modern Pathology
2014 - present Ad-hoc reviewer, Expert Review of Anticancer Therapy
2014 - present Ad-hoc reviewer, Oncoimmunology
2014 - present Ad-hoc reviewer, Pathology Research and Practice
2014 - present Ad-hoc reviewer, Tumor Biology
2015 - present Ad-hoc reviewer, Acta Oncologica
2015 - present Ad-hoc reviewer, BMC Cancer
2015 - 2017 Ad-hoc reviewer, Human Pathology
2015 - 2017 Ad-hoc reviewer, Laboratory Investigation
2015 - 2019 Ad hoc reviewer, American Journal of Surgical Pathology
2016 - present Ad-hoc reviewer, Journal of the European Academy of Dermatology and Venereology
2017 - present Ad hoc reviewer, Acta Ophthalmologica
2017 - present Ad-hoc reviewer, Cancer
2017 - present Ad-hoc reviewer, Cancer Medicine
2017 - present Ad-hoc reviewer, Journal of Investigative Dermatology
2017 - present Ad-hoc reviewer, Leukemia and Lymphoma
2018 - present Ad-hoc reviewer, Annals of Oncology
2018 - present Ad-hoc reviewer, Clinical Cancer Research
2020 - present Ad-hoc reviewer, Lancet Oncology

INVITED PRESENTATIONS - INTERNATIONAL

1995	International Drosophila Research Conference. A genetic screen for Drosophila larvae defective in feeding identifies schluckless, a transcription factor essential for foregut development.	Speaker
1995	European Drosophila Research Conference., Tübingen, Germany. Lack of Drosophila cytoskeletal tropomyosin affects head morphogenesis during larval development.	Speaker
2013	Capacitacao em GVHD - Brazil, Cutaneous Graft versus Host Disease: Principles and Case Presentation, The Albert Einstein Hospital, Sao Paulo, Brazil.	Speaker
2014	Capacitacao em GVHD - Brazil, Cutaneous Graft versus Host Disease: Principles and Case Presentation, Bello Horizonte, Brazil	Speaker
2015	Capacitacao em GVHD - Brazil, Cutaneous Graft versus Host Disease: Principles and Case Presentation. Igazu Falls, Brazil	Speaker
2016	Problems in tumor pathology. The Christie Hospital, Manchester, United Kingdom. Difficult cases in Dermatopathology.	Speaker
2016	Problems in tumor pathology. The Christie Hospital, Manchester, United Kingdom. Interface dermatitis: An approach to inflammatory skin disease in a cancer patient population	Speaker
2016	Problems in tumor pathology. The Christie Hospital, Manchester, United Kingdom. Molecular testing algorithms informing the diagnosis of melanocytic tumors	Speaker
2016	Capacitacao em GVHD - Brazil, Cutaneous Graft versus Host Disease: Principles and Case Presentation. Fortaleza, Brazil.	Speaker
2017	18th Annual Meeting of the International Society of Veterinary Pathologists at the North American Veterinary Forum. Orlando, FL. Clinical, histopathologic, immunohistochemical, and molecular features of human melanocytic tumors	Keynote Speaker
2017	The Arab School of Pathology and American University of Beirut Annual Review of Pathology. Beirut, Lebanon. Cutaneous CD30-positive lymphoproliferative disorders.	Speaker

2017	The Arab School of Pathology and American University of Beirut Annual Reivew of Pathology. Beirut, Lebanon. AJCC 8th Edition staging system for melanoma and evaluation of the sentinel lymph node	Speaker
2017	The Arab School of Pathology and American University of Beirut Annual Reivew of Pathology. Beirut, Lebanon. Update on Spitz nevi and Blue nevi with an emphasis on molecular-genetic alterations informing their diagnosis	Speaker
2017	Pathology Meeting of the A.C. Camargo Cancer Center – Skin Course, AC Camargo Cancer Center, Department of Pathology, Sao Paolo, Brazil. Merkel cell carcinoma diagnosis, pathogenesis and sentinel lymph node evaluation.	Speaker
2017	Pathology Meeting of the A.C. Camargo Cancer Center – Skin Course, AC Camargo Cancer Center, Department of Pathology, Sao Paolo, Brazil. Diagnosing cutaneous graft versus host disease: Integrating clinical information and avoiding the pitfalls.	Speaker
2017	Pathology Meeting of the A.C. Camargo Cancer Center – Skin Course, AC Camargo Cancer Center, Department of Pathology, Sao Paolo, Brazil. Immunohistochemical and molecular tests informing the diagnosis of melanocytic tumors.	Speaker
2017	Iranian Cancer Association Annual West Asia Cancer Conference, Tehran, Iran. Practical Histopathologic Considerations for Orbit and Ocular Adnexal Cancers for the ocular surgeon.	Speaker
2017	Iranian Cancer Association Annual West Asia Cancer Conference, Tehran, Iran. Update on the 8th Edition of the AJCC for Cutaneous Melanoma: What's new and what's different with a 'reflection' on ocular melanomas.	Speaker
2017	Iranian Cancer Association Annual West Asia Cancer Conference, Tehran, Iran. Sebaceous Neoplasms: Histopathology, Immunohistochemistry and Molecular studies and implications for Muir-Torre Syndrome.	Speaker
2018	Third Latin-American Orbit and Oncology Course, Bogata, Colombia. Cutaneous Merkel cell carcinoma: An update on diagnosis, staging and molecular pathogenesis	Speaker
2018	Third Latin-American Orbit and Oncology Course, Bogata, Colombia. Molecular testing that informs the diagnosis and prognosis of cutaneous melanocytic tumors: Possible applications to ocular tumors.	Speaker

2018	Third Latin-American Orbit and Oncology Course, Bogata, Colombia. Sebaceous Carcinoma of the Eyelid: Diagnosis and molecular-genetics.	Speaker
2018	Third Latin-American Orbit and Oncology Course, Bogata, Colombia. An update on the 8th Edition AJCC for cutaneous and conjunctival melanoma.	Speaker
2018	Third Latin-American Orbit and Oncology Course, Bogata, Colombia. MALT lymphoma of the eyelid: Diagnosis and Pathogenesis.	Speaker
2018	Third Latin-American Orbit and Oncology Course, Bogata, Colombia. Practical considerations for the ocular oncologic surgeon: Perspectives from the surgical pathologist.	Speaker
2018	London Dermatopathology Symposium, London, United Kingdom. Diagnosing challenging melanocytic tumors: Immunohistochemical and molecular studies that inform the diagnosis. An update and case series (short course).	Speaker
2018	London Dermatopathology Symposium, London, United Kingdom. A practical update of the 8th Edition AJCC staging system for cutaneous melanoma: What is new, what is different and what is challenging.	Speaker
2018	London Dermatopathology Symposium, London, United Kingdom. Merkel cell carcinoma: Diagnosis, molecular pathogenesis and staging.	Speaker
2018	XXXII Congress of the International Academy of Pathology (IAP). Sentinel lymph node assessment in Melanoma and Merkel cell carcinoma: Principles, pitfalls and clinical implications.	Speaker
2018	International Neoadjuvant Melanoma Consortium at the European Society for Medical Oncologists, Munich, Germany. Pathologic Assessment following neoadjuvant therapy in metastatic melanoma: Overview to specimen handling and the spectrum of pathologic changes.	Speaker
2018	International Melanoma Pathology Study Group, 11th International Melanoma Pathology Symposium of the International Melanoma Pathology Study Group, At the Society for Melanoma Research Congress, Manchester, United Kingdom. Immune checkpoint blockade and implications for the dermatopathologist: The spectrum of cutaneous toxicities in reaction to immune checkpoint blockade	Speaker

2018	Dermatopathology Update 2018, Maastricht University Medical Center, Department of Pathology, Maastricht, Netherlands. Blue nevus-like melanocytic tumors: Diagnosis and the application of molecular techniques for classification.	Speaker
2018	Dermatopathology Update 2018, Maastricht University Medical Center, Department of Pathology, Maastricht, Netherlands. Sebaceous neoplasia: Diagnosis, relationship to Muir-Tore and molecular genetics	Speaker
2018	Melanoma Institute of Australia. The density and repertoire of the T cell infiltrate correlates with patient survival in Merkel cell carcinoma.	Speaker
2018	Melanoma Institute of Australia. Prognostic factors in anorectal melanoma.	Speaker
2019	Bamberger Morphologietage, Bamberg, Germany. Merkel cell carcinoma: Diagnosis, molecular pathogenesis and staging.	Keynote Speaker
2019	University Clinic Essen Symposium "Plasticity and Cancer," West German Tumor Center, Essen, Germany. Molecular-genetic and immune studies to identify drivers and prognostic biomarkers in cutaneous oncology.	Speaker

INVITED PRESENTATIONS - NATIONAL

2007	The United States and Canadian Academy of Pathology Annual Meeting, San Diego, CA. Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues.	Poster presentation
2008	The United States and Canadian Academy of Pathology Annual Meeting, Denver, CO. A rapid in situ hybridization technique to identify miRNAs with altered expression in papillary thyroid carcinoma.	Poster presentation
2008	American Society of Dermatopathology Annual Meeting, Baltimore, MD. A Case Series of Angiomatoid Spitz Nevus.	Poster presentation
2009	The United States and Canadian Academy of Pathology Annual Meeting, Boston, MA. Cyclin D1 expression as a marker of papillary thyroid carcinoma.	Poster presentation

2010	American Society of Dermatopathology Annual Meeting, Atlanta, GA. Cutaneous Abdominal Mass in an African child with Human Immunodeficiency Virus: Epstein Barr Virus-Associated Leiomyosarcoma. Report of a case and review of the literature of leiomyosarcomas in HIV-infected children.	Poster presentation
2010	American Society of Dermatopathology Annual Meeting, Atlanta, GA. Fox-Fordyce disease in a patient following axillary laser hair removal.	Poster presentation
2010	American Society of Dermatopathology Annual Meeting, Atlanta, GA. Granulomatous pigmented purpuric dermatosis: report of three cases and a review of the literature.	Poster presentation
2011	The American Academy of Dermatology. 69th Annual Meeting New Orleans, LA. Basic Dermatopathology Course. Dermal Disorders and Cutaneous Deposits	Speaker
2011	American Society of Dermatopathology Annual Meeting, Seattle, WA. Bi-clonal, multifocal primary cutaneous marginal zone B cell lymphoma.	Poster presentation
2012	The American Academy of Dermatology. 70th Annual Meeting San Diego, CA. Basic Dermatopathology Course. Dermal Disorders and Cutaneous Deposits	Speaker
2012	The United States and Canadian Academy of Pathology, Annual Meeting, Vancouver, British Columbia, Canada. Loss of microRNA-205 Expression is Associated with Melanoma Progression.	Poster presentation
2012	The United States and Canadian Academy of Pathology, Annual Meeting, Vancouver, British Columbia, Canada. The utility of ATF3 in distinguishing among cutaneous epithelial neoplasms.	Poster presentation
2012	Association of Clinical Research Professionals, Global Conference, Houston, TX. Immunohistochemical and molecular studies in the diagnosis of melanocytic tumors	Speaker
2013	The United States and Canadian Academy of Pathology Annual Meeting, Baltimore, MD. Immunodetection Of Phosphohistone H3 (PHH3) As A Surrogate Of Mitotic Figure Count And Clinical Outcome In Cutaneous Melanoma.	Speaker

2013	The United States and Canadian Academy of Pathology Annual Meeting, Baltimore, MD. Diagnosing Ambiguous Melanocytic Tumors In A Tertiary Referral Center: The Contribution Of Fluorescence In Situ Hybridization (FISH) To Conventional Histopathologic And Immunophenotypic Analyses.	Speaker
2013	The Association for Research in Vision and Ophthalmology, Seattle, WA. Molecular-genetic characterization of Sebaceous Neoplasms.	Speaker
2013	The American Academy of Dermatology. 71st Annual Meeting Miami, FL. Basic Dermatopathology Course. Dermal Disorders and Cutaneous Deposits	Speaker
2013	American Society of Clinical Pathology, Annual Meeting Chicago, IL Limited Tissue Samples in the Era of Personalized Medicine: Diagnostic Challenges, Molecular analysis and Controversies	Speaker
2013	American Society of Clinical Pathology, Annual Meeting Chicago, IL. Developing Trends in Melanoma: Application of Ancillary Techniques for Diagnosis and Prognosis, Use of New Targeted Therapies and their Associated Cutaneous Side Effects	Speaker
2013	American Society of Dermatopathology, Annual Meeting, Washington, DC. Pigmented Extramammary Paget Disease of the Thigh Mimicking a Melanocytic Lesion: A Diagnostic Pitfall and Review of the Literature.	Poster presentation
2014	American Society of Clinical Pathology, Annual Meeting, Tampa Bay, FL. Developing Trends in Melanoma: Application of Ancillary Techniques for Diagnosis and Prognosis, Use of New Targeted Therapies and their Associated Cutaneous Side Effects	Speaker
2014	American Society of Dermatopathology, Annual Meeting, Chicago, IL Emerging and informative biomarkers in dermatopathology (Course: "What's New in Dermatopathologists?")	Speaker
2014	The United States and Canadian Academy of Pathology, Annual Meeting, San Diego, CA. p40 Improves Diagnostic Specificity between Atypical Fibroxanthoma and Poorly Differentiated Squamous Cell Carcinoma.	Poster presentation
2014	The United States and Canadian Academy of Pathology, Annual Meeting, San Diego, CA. Shared Clonality in Distinctive Lesions of Lymphomatoid Papulosis and Mycosis Fungoides Occuring in the Same Patients Suggests a Common Origin.	Poster presentation

2014	The United States and Canadian Academy of Pathology, Annual Meeting, San Diego, CA. Clinical Next Generation Sequencing (NGS) Identifies a Subset of Melanoma Harboring SMARCB1 Mutations.	Poster presentation
2014	The United States and Canadian Academy of Pathology, Annual Meeting, San Diego, CA. Tumor Size Correlates with Survival in Melanomas Associated with Conventional or Cellular Blue Nevi or Displaying Blue Nevus-Like Features (So Called Malignant Blue Nevus).	Poster presentation
2015	American Academy of Dermatology, Summer Meeting. New York, NY. Emerging biomarkers informing the practice of dermatopathology	Speaker
2015	The United States and Canadian Academy of Pathology, Annual Meeting, Boston, MA. Differentially Expressed miRNAs Implicate Pathways in Sebaceous Carcinomas and Adenomas.	Poster presentation
2015	The United States and Canadian Academy of Pathology, Annual Meeting, Boston, MA. The Contribution of Second Generation Fluorescence In Situ Hybridization (FISH) To histopathologic and Immunophenotypic Analyses in the Diagnosis of Ambiguous Melanocytic Tumors	Poster presentation
2015	The United States and Canadian Academy of Pathology, Annual Meeting, Boston, MA. Utility of BRAFV600E Immunohistochemistry (IHC) Expression Pattern as a Surrogate of BRAFV600 Mutation Status in 154 Patients With Advanced Stage Melanoma	Poster presentation
2015	The United States and Canadian Academy of Pathology, Annual Meeting, Boston, MA. The Impact of Second-Opinion Dermatopathology Review on Melanoma Management and Stage at a Tertiary Cancer Referral Center: A Quality Control Study.	Poster presentation
2015	American Society of Dermatopathology, Annual Meeting, San Francisco, CA. Self Assessment Course	Speaker
2015	American Society of Clinical Pathology, Annual Meeting, Long Beach, CA. Graft versus host disease: Principles and case presentations.	Speaker
2015	American Society of Clinical Pathology, Annual Meeting, Long Beach, CA. Developing Trends in Melanoma: Application of Ancillary Techniques for Diagnosis and Prognosis, Use of New Targeted Therapies and their Associated Cutaneous Side Effects	Speaker

2016	American Academy of Dermatology, Annual Meeting, Washington DC. Melanoma and the Genes: Molecular-genetic approaches to diagnosis and treatment of melanoma	Speaker
2016	United States and Canadian Academy of Pathology, Annual Meeting, Seattle, WA. Next Generation Sequencing identifies high frequency of clinically actionable mutations in sebaceous carcinoma.	Speaker
2016	United States and Canadian Academy of Pathology, Annual Meeting, Seattle, WA. Composition, density and distribution of the inflammatory infiltrate correlates with prognosis in Merkel Cell Carcinoma	Poster presentation
2016	United States and Canadian Academy of Pathology, Annual Meeting, Seattle, WA. Evening Slide Symposium: Difficult cases in a tertiary referral center.	Speaker
2016	American Academy of Dermatology, Summer Meeting, Boston, MA. Molecular Genetics of Cutaneous Sebaceous Neoplasia and Implications for Targeted Therapy	Speaker
2016	American Society of Clinical Pathology, Annual Meeting, Las Vegas, NV. Developing Trends in Melanoma: Application of Ancillary Techniques for Diagnosis and Prognosis and Diagnostic Reporting of Primary Cutaneous Melanoma	Speaker
2016	American Society of Clinical Pathology, Annual Meeting, Las Vegas, NV. Graft versus Host Disease: Clinical considerations and Histopathologic features of cutaneous, gastrointestinal and hepatic graft versus host disease.	Speaker and course organizer
2016	American Society of Clinical Pathology, Annual Meeting, Las Vegas, NV. Molecular testing informing diagnosis and prognosis of cutaneous melanocytic proliferations.	Speaker
2016	American Society of Dermatopathology, 53rd Annual Meeting, Chicago, IL. Oral Abstract Session.	Moderator
2016	Society of Melanoma Research, Boston, MA. Pathologic assessment following neoadjuvant systemic therapy	Speaker
2017	American Academy of Dermatology, Annual Meeting, Orlando FL. Melanoma and the Genes: Molecular-genetic approaches to diagnosis and treatment of melanoma	Speaker
2017	8th Annual DermPedia Dermatopathology Symposium. San Diego, CA. Blue nevus and blue nevus-like lesions: An integrated histopathologic and molecular genetic classification.	Speaker

2017	8th Annual DermPedia Dermatopathology Symposium. San Diego, CA. Diagnosis, molecular pathogenesis and pathology of Merkel Cell Carcinoma.	Speaker
2017	8th Annual DermPedia Dermatopathology Symposium. San Diego, CA. PD-L1 Immunohistochemical studies in dermatopathology: Challenges and pitfalls to clinical interpretation	Speaker
2017	8th Annual DermPedia Dermatopathology Symposium. San Diego, CA. Towards a molecular classification of Spitzoid neoplasia.	Speaker
2017	Cambridge Health Institute, Biomarkers and Immuno-Oncology Summit, Philadelphia, PA. Immune infiltrates as biomarkers of response and prognosis in cancer	Speaker
2017	American Society for Clinical Pathology, Annual Meeting, Chicago, IL. Developing Trends in Melanoma: Application of Ancillary Techniques for Diagnosis and Prognosis, Use of New Targeted Therapies and Update on the 8th Edition of the AJCC staging system.	Speaker and course organizer
2017	Great Lakes Pathology Conference, Pathology Education Partners, Traverse City, MI. Cutaneous reactions to oncologic therapy and a practical guide to PD-L1 immunohistochemistry.	Speaker
2017	Great Lakes Pathology Conference, Pathology Education Partners, Traverse City, MI. Update on the 8th Edition of the AJCC for Cutaneous Melanoma: What's new and what's different	Speaker
2017	54th Annual Meeting of the American Society of Dermatopathology, Chicago, IL. Evening Slide Symposium.	Speaker
2017	International Neoadjuvant Melanoma Consortium. Society of Melanoma Research. Pathologic considerations for neoadjuvant treated melanoma specimens.	Speaker
2018	Hawai Dermatopathology Conference, Pathology Education Partners, Maui, HI. Cutaneous reactions to oncologic therapy and a practical guide to PD-L1 immunohistochemistry.	Speaker
2018	Hawai Dermatopathology Conference, Pathology Education Partners, Maui, HI. Merkel cell carcinoma: Diagnosis, pathogenesis, staging, sentinel lymph node evaluation and emerging therapeutics.	Speaker

2018	Hawai Dermatopathology Conference, Pathology Education Partners, Maui, HI. Update on blue nevi and blue-nevus like lesions: Emphasis on morphology and a correlation with molecular-genetic alterations.	Speaker
2018	Hawai Dermatopathology Conference, Pathology Education Partners, Maui, HI. Update on the 8th Edition of the AJCC for Cutaneous Melanoma: What's new and what's different.	Speaker
2018	North American Society of Head and Neck Pathology. The United States and Canadian Academy of Pathology. Merkel cell carcinoma: An update on diagnosis, genetics, staging and therapy.	Speaker
2018	The United States and Canadian Academy of Pathology, Vancouver, British Columbia, Canada. Clinical and histopathologic correlates of survival in anorectal melanoma: Stage at presentation is a key driver.	Speaker
2018	9th Annual DermPedia Dermatopathology Symposium, DermPedia, San Diego, CA. Diagnosing cutaneous graft versus host disease: integrating clinical and pathologic features to make an accurate diagnosis and exclude mimics.	Speaker
2018	9th Annual DermPedia Dermatopathology Symposium, DermPedia, San Diego, CA. Challenging melanocytic lesions from my consultation practice.	Speaker
2018	9th Annual DermPedia Dermatopathology Symposium, DermPedia, San Diego, CA. PD-L1 Immunohistochemical studies: Interpretation, pitfalls and practical considerations.	Speaker
2018	9th Annual DermPedia Dermatopathology Symposium, DermPedia, San Diego, CA. Secondary syphilis: Diagnosis of a stealthy entity.	Speaker
2018	Napa Dermatopathology Conference, Pathology Education Partners, Napa, CA. Immune checkpoint blockade and implications for the dermatopathologist: Interpreting PD-L1 immunohistochemical studies and cutaneous toxicities in the context of immune checkpoint blockade.	Speaker
2018	Napa Dermatopathology Conference, Pathology Education Partners, Napa, CA. Merkel cell carcinoma: Diagnosis, molecular pathogenesis and staging.	Speaker
2018	Napa Dermatopathology Conference, Pathology Education Partners, Napa, CA. Sebaceous neoplasia: Diagnosis and implications for DNA mismatch repair testing and the Muir-Torre syndrome.	Speaker

2018	Great Lakes Pathology Conference, Pathology Education Partners, Traverse City, MI. Immune checkpoint blockade and implications for the dermatopathologist: Interpreting PD-L1 immunohistochemical studies and cutaneous toxicities in the context of immune checkpoint blockade.	Speaker
2018	Great Lakes Pathology Conference, Pathology Education Partners, Traverse City, MI. Pigmented lesions of the anogenital tract.	Speaker
2018	Great Lakes Pathology Conference, Pathology Education Partners, Traverse City, MI. Update on blue nevi: Pathology, molecular genetics and diagnosis.	Speaker
2018	American Society for Clinical Pathology, Annual Meeting, Baltimore, MD. Update to the 8th Edition AJCC staging systems for cutaneous malignancies,	Speaker
2018	Cambridge Health Institute, Biomarkers and Immunology Summit. Boston, MA. Immune-based prognostic markers in Merkel Cell Carcinoma.	Speaker
2018	55th Annual Meeting of the American Society of Dermatopathology, Chicago, IL. Neoadjuvant therapy in melanoma: Assessment of the pathology specimens (Melanoma short course)	Speaker
2018	55th Annual Meeting of the American Society of Dermatopathology, Chicago, IL. Updates to the 8th Edition AJCC Staging system for cutaneous malignancies	Speaker
2019	American Academy of Dermatology, Annual Meeting, Washington, DC. Cutaneous infections: What to look for and how to avoid the pitfalls: Reflections from a tertiary cancer referral center	Speaker
2019	American Academy of Dermatology, Annual Meeting, Washington, DC. Merkel Cell Carcinoma International Working Group. Merkel cell carcinoma: T-cell quantity and quality matter.	Speaker
2019	American Academy of Dermatology, Annual Meeting, Washington, DC. Staging primary cutaneous melanoma: Update to the 8th Edition AJCC criteria	Speaker
2019	American Academy of Dermatology, Annual Meeting, Washington, DC. Advanced Self Assessment in Dermatopathology.	Speaker
2019	International Neoadjuvant Melanoma Consortium at the American Society of Clinical Oncology, Chicago, IL. Pathologic Assessment of Neoadjuvant Treated Melanoma Specimens	Speaker

2019	Partnership for Accelerating Cancer Therapies (PACT) Joint Immune Oncology Coordination Forum, American Society of Clinical Oncology, Chicago, IL. Immunohistochemical and multiplex immunofluorescence working group harmonization summary.	Speaker
2019	United States and Canadian Academy of Pathology. Annual Meeting. Infectious disease evening specialty conference. Condyloma Lata masquerading as anal squamous cell carcinoma: The many challenges of secondary syphilis.	Speaker
2019	United States and Canadian Academy of Pathology. Annual Meeting. Long Course, Washington, DC. Lethality can be only skin deep: Aggressive epidermal carcinomas. Diagnosis, molecular-genetic drivers, staging and therapeutic advances.	Speaker
2019	Napa Dermatopathology Conference, Pathology Education Partners, Napa, CA. Blue nevus and blue nevus-like lesions: Diagnosis and molecular genetics	Speaker
2019	Napa Dermatopathology Conference, Pathology Education Partners, Napa, CA. Oncodermatopathology: Molecular testing informing treatment decisions and cutaneous toxicities associated with novel cancer therapies	Speaker
2019	Napa Dermatopathology Conference, Pathology Education Partners, Napa, CA. Staging primary cutaneous melanoma: Update to the 8th Edition AJCC criteria. Practical tips for the practicing pathologist	Speaker
2019	Alliance for Clinical Trials, Spring Meeting. Update on the CIMAC laboratories.	Speaker
2019	London Dermatopathology Symposium, London, United Kingdom. Oncodermatopathology: An overview of Biomarkers informing therapy in cutaneous malignancy and the toxicities that develop from those therapies (short course)	Speaker
2019	London Dermatopathology Symposium, London, United Kingdom. The Importance of Clinical Pathologic Correlation in Dermatopathology	Speaker
2019	The American Society of Clinical Pathology, Annual Meeting, Phoenix, AZ. Biomarker interpretation and pathologic features of cutaneous and gastrointestinal toxicities to immune checkpoint blockade.	Speaker

2019	Maui Dermatopathology Conference, Pathology Education Partners. Cutaneous Reactions to Immune Checkpoint Blockade: The advent of Oncodermatopathology.	Speaker
2019	Maui Dermatopathology Conference, Pathology Education Partners. Merkel cell carcinoma: Diagnosis, staging, molecular-genetics, and therapeutic advances.	Speaker
2019	Maui Dermatopathology Conference, Pathology Education Partners. Pigmented lesions of the anogenital tract: Diagnosis and staging	Speaker
2019	Maui Dermatopathology Conference, Pathology Education Partners. Sebaceous neoplasia: Diagnosis, molecular-genetics and relationships to Muir-Torre Syndrome.	Speaker
2019	Maui Dermatopathology Conference, Pathology Education Partners. Molecular-genetic alterations of Blue nevi and blue nevus-like lesions: Morphology reflects genetics	Speaker
2019	Scientific Symposiums International, Maui, HI. Benign adnexal tumors: Diagnosis, molecular-genetics and prognostic biomarkers.	Speaker.
2019	Scientific Symposiums International, Maui, HI. Malignant adnexal neoplasms: Diagnosis, molecular-genetics and prognostic biomarkers.	Speaker
2019	Scientific Symposiums International, Maui, HI. Sebaceous neoplasia and Merkel cell carcinoma: Diagnosis, molecular-genetics and staging.	Speaker
2019	Scientific Symposiums International, Maui, HI. Cutaneous reactions to immune checkpoint blockade: The advent of Oncodermatopathology	Speaker
2019	56th Annual Meeting, American Society of Dermatopathology, Young Physicians Forum (Myriad Genetics), San Diego, CA. Molecular testing in melanocytic tumor diagnosis.	Speaker
2019	56th Annual Meeting, American Society of Dermatopathology, San Diego, CA. Neoadjuvant therapy in Melanoma: The role of the pathologist	Speaker
2019	56th Annual Meeting, American Society of Dermatopathology, San Diego, CA. Self-Assessment in Dermatopathology	Speaker
2019	56th Annual Meeting, American Society of Dermatopathology, San Diego, CA. Principles of staging anogenital melanomas: To AJCC or not to AJCC?	Speaker

2019	Melanoma Research Alliance (MRA), Washington, DC. Neoadjuvant Therapy in Melanoma: Clinical trial design and pathologic assessment. Panel discussion.	Panel discussant
2019	National Cancer Institute (NCI) and Partnership for the Acceleration of Cancer Therapy (PACT), National Institutes of Health (NIH) CIMAC-CIDC Tier 1 Assays Harmonization and CIDC Update. Update on Harmonization of multiplex immunofluorescence assays for the NCI-CIMAC	Speaker
2019	The Alliance for Clinical Trials, Fall Meeting, Chicago, IL. Update on National Cancer Institute Cancer Immune Monitoring and Analysis Centers (NCI-CIMAC).	Speaker
2019	Society for Melanoma Research, Plenary Session, Salt Lake City, UT. Histopathologic patterns of response predict recurrence free survival following neoadjuvant dabrafenib/tremetinib in Stage III melanoma.	Speaker
2019	Society for Melanoma Research, Pathology Interest Group, Salt Lake City, UT. Neoadjuvant Therapy in Melanoma: The importance of the pathologic assessment.	Speaker
2020	Southwestern Oncology Group (SWOG), Melanoma Committee, "Towards a pathologic definition of response in neo-adjuvant therapy – implications for S1801"	Speaker
2020	Melanoma versus the Pandemic - an interactive ZOOM meeting, The Moffitt Cancer Center and AIM at Melanoma Foundation	Panelist

INVITED PRESENTATIONS - REGIONAL AND OTHER INVITED PRESENTATIONS

2002	Baylor College of Medicine Medical Scientist Training Program, Annual retreat, Woodlands, TX. Cyclin F disruption compromises placental development and affects normal cell cycle execution.	Speaker
2003	Baylor College of Medicine Medical Scientist Training Program, Annual retreat, Galveston, TX. Defective cardiovascular development and elevated cyclin E and Notch proteins in mice lacking the Fbw7 F-box protein.	Speaker
2011	The University of Texas at MD Anderson Cancer Center, Institutional Grand rounds, Houston, TX. What are the tools in the toolbox? Histopathologic, immunohistochemical and molecular studies that inform the diagnosis of melanocytic tumors.	Speaker

2013	The University of Texas MD Anderson Cancer Center, Department of Pathology, Diagnostic Pathology Course, Houston, TX. Histopathologic, immunohistochemical and molecular studies that inform the diagnosis of melanocytic tumors.	Speaker
2013	The Methodist Hospital, Department of Pathology, Grand Rounds, Houston, TX. Graft versus host disease: Principles and case presentations.	Speaker
2014	The Methodist Hospital, Department of Pathology, Grand Rounds, Houston, TX. Molecular Testing to inform the diagnosis of challenging melanocytic tumors.	Speaker
2015	The University of Texas MD Anderson Cancer Center. Advances in Orbital Oncology and Oculofacial Plastic Surgery Molecular Testing for Orbital and Ocular Adnexal Cancers	Speaker
2015	The Methodist Hospital, Department of Pathology, Grand Rounds, Houston, TX. Distinguishing melanoma from melanocytic nevi and AJCC staging parameters in reporting the diagnosis of melanoma.	Speaker
2015	Dartmouth Hitchcock Medical Center, Department of Dermatology, Grand Rounds, Lebanon, NH. Immunohistochemical and molecular studies informing the diagnosis of melanocytic tumors	Speaker
2016	The Hospital of the University of Pennsylvania, Department of Pathology and Laboratory Medicine, Grand Rounds, Philadelphia, PA. Molecular-Genetic Alterations in Sebaceous Carcinoma	Speaker
2016	Meredith's Mission for Melanoma. First Annual Gala and Fundraiser. An Overview of the Melanoma Moonshot Program at MD Anderson Cancer Center.	Keynote Speaker
2016	The University of Texas MD Anderson Cancer Center, Departments of Surgical and Medical Oncology, Houston, TX. The Art and Science of Managing the NEW Melanoma Landscape: A Case-Based Multidisciplinary Approach. Metastatic melanoma: Immunotherapy, Targeted therapy and Multi-disciplinary care: Challenging cases in management of metastatic melanoma (A multidisciplinary case panel).	Panelist
2016	The University of Texas MD Anderson Cancer Center, Melanoma Management Course, Global Academic Oncology Program, Houston, TX. Challenging cases in management of metastatic melanoma (A multidisciplinary case panel).	Panelist

2017	The University of Texas MD Anderson Cancer Center. Advances in Orbital Oncology and Oculofacial Plastic Surgery. Practical histopathologic and molecular considerations for orbital and ocular adnexal cancers: An integrated approach.	Speaker
2017	The Hospital of the University of Pennsylvania, Department of Dermatology, Philadelphia, PA. Morphologic, immunohistochemical and molecular-genetic studies in cutaneous oncology.	Speaker
2017	The University of Texas MD Anderson Cancer Center, Department of Surgery. Melanoma Core Winter Seminar Series. Precursor melanocytic lesions: How we distinguish benign from malignant?	Speaker
2017	The University of Texas MD Anderson Cancer Center, Departments of Surgical and Medical Oncology, Houston, TX. The Art and Science of Managing the NEW Melanoma Landscape: A Case-Based Multidisciplinary Approach. Tissue based biomarkers directing management of patients with metastatic melan	Speaker and Panelist
2017	The University of Texas MD Anderson Cancer Center, Global Academic Programs, Medical Educational Program on Melanoma Management, Houston, TX. Pathology and the management of melanoma patients: Diagnosis, prognosis and biomarkers informing therapeutic decisions	Speaker
2018	Annual Meeting of Houston Society of Clinical Pathologists, Houston, TX. Molecular testing informing the diagnosis of challenging melanocytic tumors.	Speaker
2018	Myriad Genetics, Salt Lake City, UT. Next generation sequencing studies to identify copy number alterations in the diagnosis of melanocytic tumors	Speaker
2018	The University of Texas MD Anderson, Department of Pathology Immuno-Oncology Retreat, Houston, TX. Correlative studies in neoadjuvant treatment of stage III melanoma.	Speaker
2018	The University of Texas MD Anderson, Department of Translational and Molecular Pathology, Annual Departmental Retreat, Houston, TX. Immune and molecular studies in cutaneous oncology.	Speaker
2018	The University of Texas MD Anderson, Department of Cancer Prevention, Understanding Pre-Cancer Evolution Retreat, Bellaire, TX. The progression from precursor nevi (dysplastic and others) to invasive melanoma	Speaker

2019	Albert Einstein College of Medicine, Department of Dermatology, Annual Dermatopathology Symposium, Bronx, NY. Molecular and Immunophenotypic studies informing the diagnosis of challenging melanocytic lesions.	Speaker
2019	San Diego Dermatology Society, Annual Meeting, San Diego, CA. Molecular and Immunophenotypic studies informing the diagnosis of challenging melanocytic lesions	Keynote Speaker
2019	Harvard Dermatopathology Annual Course, Department of Pathology, Harvard Medical School, Boston, MA. Update on Blue nevus and Spitzoid lesions: Morphologic features and molecular-genetic alterations informing the diagnosis and management.	Speaker
2019	Harvard Dermatopathology Annual Course, Department of Pathology, Harvard Medical School, Boston, MA. A Historical overview of molecular testing that informs the diagnosis of challenging melanocytic lesions	Speaker
2019	Harvard Dermatopathology Annual Course, Department of Pathology, Harvard Medical School, Boston, MA. Challenging cases from my consultation practice.	Speaker
2019	Nanostring Board of Directors Meeting, Vancouver, British Columbia, Canada. Multi-modal imaging in human tumor tissue: The past, the present and the future.	Speaker

CONTINUING EDUCATION AND PROFESSIONAL DEVELOPMENT ACTIVITIES

2019	'The Art of Negotiations and Difficult Discussions', Leadership Retreat, The University of Texas MD Anderson Cancer Center, Houston, TX
2019	College of American Pathologists (CAP) Engaged Leadership Academy (ELA), Chiacgo, IL.

UNIVERSITY AND PUBLIC SERVICE

SERVICE ACTIVITIES SUMMARY

Since beginning my position at MD Anderson, I have served on a number of institutional committees. Since I received an Institutional Review Grant (IRG) in my first year on faculty, I was subsequently asked to serve on the IRG Grant Review Committee beginning in 2012, which collectively reviews approximately 50-75 internal grant applications twice annually. Similarly, in 2015, I was asked to serve on a similar committee, The Sister Institution Network Fund Grant Review Committee, which reviews internal applications made by MD Anderson faculty in conjunction with faculty from our sister institutions from around the world. The goal of this seed money (ranges from 75K-125K) is to foster inter-institutional collaborations and leverage resources unique to each institution. This was a very rewarding service as I had the privilege to witness a number of important global collaborations take root. Beginning in 2017, I was asked to serve on the IRG Executive Committee which oversees funding cut offs and determines granting allocations.

In 2015, I was elected by colleagues in The Department of Pathology to represent them on the Physicians Referral Service (PRS) Budget and Finance Committee for a two year term. This is a very important institutional committee that provides physician input to institutional leadership regarding annual budgetary goals and benchmarks. Finally, I have been asked to serve on a number of institutional committees including the ICD-10 Implementation Committee and two faculty search committees, including the search for the Chairman of the Department of Lymphoma and Myeloma in 2019.

SERVICE AT OTHER UNIVERSITIES

2007 - 2009	Resident Education/Didactics Coordinator, Department of Pathology and Laboratory Medicine	Hospital for the University of Pennsylvania, Philadelphia PA
2008 - 2009	Surgical Pathology Resident Committee, Department of Pathology and Laboratory Medicine	Hospital for the University of Pennsylvania, Philadelphia PA
2008 - 2009	Resident Education Operating Committee, Department of Pathology and Laboratory Medicine	Hospital for the University of Pennsylvania, Philadelphia PA
2013 - 2014	ICD-10 Physician Ambassador Program, Ambassador, Department of Pathology	The University of Texas MD Anderson Cancer Center, Houston, Texas
2012 - present	Institutional Grant Review Committee, Member	The University of Texas MD Anderson Cancer Center, Houston, Texas
2015 - 2016	Physicians Referral Service, Budget and Finance Committee	The University of Texas MD Anderson Cancer Center, Houston, Texas
2015 - 2017	Sister Institution Network Funds, Grant Review Committee, Member	The University of Texas MD Anderson Cancer Center, Houston, Texas

2017 - present	Institutional Grant Review Executive Committee, Member	The University of Texas MD Anderson Cancer Center, Houston, Texas
2019 - 2019	Lymphoma/Myeloma Chairman Search Committee, Member	The University of Texas MD Anderson Cancer Center, Houston, Texas
2019 - present	Translational and Molecular Pathology Associate Professor Search Committee, Member	The University of Texas MD Anderson Cancer Center, Houston, Texas

TEACHING SUMMARY

Since my earliest days of medical school, I have been committed to teaching histology and pathology. As a graduate student, I served as a teaching assistant in the medical student histology laboratories and twice won the Ilmar Kuisk Outstanding Senior Teaching Assistant Award, selected by the medical students from their Histology and Cell Biology Course. I continued this during my residency in Anatomic Pathology at The Hospital of the University of Pennsylvania, teaching in the student pathology laboratories throughout my 4 year residency but also leading numerous Resident Education Committees designed to completely restructure Resident Education both in the form of didactic structure and clinical rotations. My efforts towards resident and medical student education culminated in my being awarded The Ronni A. Ladoto Residence Excellence in Teaching Award.

Since beginning my faculty position at The University of Texas MD Anderson Cancer Center, teaching residents and fellows at the microscope and in didactic sessions has been a central component of my daily activities--both at MD Anderson and in conjunction with other institutions in the Texas Medical Center (The Methodist Hospital, in particular). I have mentored trainees both in their clinical education as well as in a variety of translational research projects, including as a PhD advisor. In addition, I have been leading our institutional College of American Pathologists Pathology in Practice (CAP-PIP) activities since 2014. In this capacity, I work with the fellows to research and present 10 cases every 3 months during their fellowship in our Department. Finally, I have been an invited speaker at numerous Continuing Medical Education activities, including at National meetings (The United States and Canadian Academy of Pathology, The American Society for Clinical Pathology, The American Society of Dermatopathology, and The American Academy of Dermatology) and numerous private CME courses around the world.

RESEARCH AND CREATIVE ACTIVITIES

RESEARCH AWARDS - CURRENT

1.5 R01 CA187076-05	Collaborator	1.2 CM % effort	Hwu/Davies (PI)
NIH		08/13/2015-	07/31/2020
The role of the P13K pathway in immune resistance		\$ 207,500	
		direct/yr 1	

Goals: To determine the significance of the PI3K signaling pathway in melanoma and in particular the relationship(s) with the associated immune infiltrate.

Characterization of immune infiltrates in human and mouse melanoma tissues.

2. FP00000184	Collaborator	0.36 CM % effort	McQuade (PI)
Conquer Cancer Foundation		07/01/2017	06/30/2020
Molecular, Immune and Clinical Significance of Obesity in Advanced Melanoma		\$ 200,000 direct/yr 1	
To understand mechanisms by which obesity impacts patient responses to therapy. We will perform comprehensive molecular and immunohistochemical profiling to understand this phenomenon.			
3. W81XWH1810146 - CA170374P2	PI	0.96 CM % effort	Tetzlaff, Davies, Gershenwald (PI)
Department of Defense		07/15/2018	07/14/2021
Integration of Clinical, Molecular, and Immune Features to Improve Risk Stratification and Outcomes in Melanoma Patients with Sentinel Lymph Node Metastasis		\$ 563,422 direct/yr 1	\$ 1,690,366 total
Perform an integrated analysis of the clinical, pathological, molecular and immune features of melanoma patients with microscopic regional lymph node involvement in order to improve risk models and clinical outcomes.			
Systematic characterization of sentinel lymph node (SLN) metastases and performance of Nanostring DSP (GeoMX) digital spatial profiling to identify molecular surrogates of disease progression among patients with clinically occult stage III regionally metastatic melanoma.			
4. 1U24CA224285-01R	Collaborator	1.2 cm % effort	Wistuba (PI)
National Cancer Institute		09/30/2017	06/30/2022
Translational Cancer Immune Monitoring and Analysis Center (TCIMAC)			\$ 11,000,000 total
The main goals of TCIMAC are to: 1) provide centralized and harmonized services for sample collection, processing and quality assurance, and 2) use analytically-validated and standardized assays and platforms to offer state-of-the-art analyses for patients enrolled on NCI- sponsored early phase immunotherapy clinical trials.			
I co-chair the multiplex immunofluorescence working group.			
5. 55905	Collaborator	0.24 CM % effort	Sharma (PI)
Parker Institute of Cancer		08/01/2018	07/31/2025
2017-0446 An Exploratory Study of Nivolumab with or without Ipilimumab According to Tumor CD8 Expression in Patients with Advanced Cancer			\$ 334,526 total
To determine the utility of percentage of CD8-positive tumor associated T-cells as an integral biomarker in clinical trial interrogating the efficacy of single agent versus combination immune checkpoint blockade across cancer types.			

Developed CLIA-certified assay to quantify CD8% in pre- and on-treatment human tissue biopsy specimens as integral and integrated biomarker for patients receiving single agent versus combination immune checkpoint blockade across cancer types.

RESEARCH AWARDS - SUBMITTED

1.	Co-PI	1.2 CM % effort	Amaria and Tetzlaff (PI)
	Melanoma Research Alliance Team Science Award	01/01/2021	12/31/2024
	Identifying features that correlate with clinical outcomes among patients treated with neoadjuvant dabrafenib and trametinib.		
	To identify clinical, histological, molecular and immune features will correlate with clinical outcomes among pCR and non-pCR patients treated with neoadjuvant dabrafenib and trametinib.		
	Comprehensive characterization of histological, molecular and immune features in pre-, on- and post-treatment specimens of patients with stage III BRAF V600E/K metastatic melanoma.		

RESEARCH AWARDS - PAST

1.	RP160183	Collaborator	0.36 CM % effort	Davies (PI)
	Cancer Prevention Research Institute of Texas		03/01/2016	08/28/2019
	Exploiting molecular and metabolic dependencies to optimize personalized therapeutic approaches for melanomas		\$ 285,000	direct/yr 1
	Exploit metabolic dependencies to overcome resistance to targeted therapies for melanoma.			
	Characterization of human and mouse tissues by histopathologic and immunohistochemical interrogations			
<hr/>				
2.	W81XWH-16-1-0120	CO-PI	0.6 CM % effort	Wargo, Herlyn, Tetzlaff (PI)
	Department of Defense		09/30/2016	09/29/2019
	Understanding the Immune Biology of Checkpoint inhibitors to Develop New Strategies for Therapy			
	To determine the immunological mechanisms leading to response or resistance to recently approved immune checkpoint inhibitors, Nivolumab and Ipilimumab. The potential benefits of these studies include identifying patients who have a greater possibility of tolerating and responding to therapy versus not response to treatment.			
	Comprehensive tissue characterization (Whole exome sequencing, RNA sequencing, and immunohistochemical studies) on tissue before, during and after immune checkpoint blockade therapy.			
<hr/>				
3.	RP170317	Collaborator	0.12 CM % effort	Woodman (PI)
	Cancer Prevention Research Institute of Texas		12/01/2016	11/30/2019
	Developing Effective Immunotherapeutic Strategies for Advanced Uveal Melanoma		\$ 284,885	direct/yr 1

To perform comprehensive immune profiling of uveal melanoma patient samples to identify informative biomarkers of clinical response/resistance to therapy

Perform comprehensive immune profiling of uveal melanoma patient samples and integrated findings with indices of clinical outcome

4. 712422	Collaborator	0.6 CM % effort	Samuels (PI)
	Melanoma Research Alliance	07/01/2016	06/14/2019
	Identifying somatic and microbial neo-antigens associated with melanoma responses	\$ 100,000 direct/yr 1	\$ 300,000 total

The major goal of this project is to identify somatic and microbial neo-antigens associated with melanoma responses to immune checkpoint blockade using genomic and novel proteomic approaches.

Characterization of human and mouse tissues by histopathologic and immunohistochemical interrogations

PEER REVIEWED PUBLICATIONS

1. Skipper JK, Young LJ, Bergeron JM, Tetzlaff MT, Osborn CT, Crews D. Identification of an isoform of the estrogen receptor messenger RNA lacking exon four and present in the brain. *Proc Natl Acad Sci U S A* 90(15):7172-5, 8/1993. PMID: PMC47098.
2. Tetzlaff MT, Jackle H, Pankratz MJ. Lack of Drosophila cytoskeletal tropomyosin affects head morphogenesis and the accumulation of oskar mRNA required for germ cell formation. *EMBO J* 15(6):1247-54, 3/1996. PMID: PMC450027.
3. Sanchez Y, Bachant J, Wang H, Hu F, Liu D, Tetzlaff M, Elledge SJ. Control of the DNA damage checkpoint by chk1 and rad53 protein kinases through distinct mechanisms. *Science* 286(5442):1166-71, 11/1999. PMID: 10550056.
4. Zinke I, Kirchner C, Chao LC, Tetzlaff MT, Pankratz MJ. Suppression of food intake and growth by amino acids in Drosophila: the role of pumless, a fat body expressed gene with homology to vertebrate glycine cleavage system. *Development* 126(23):5275-84, 12/1999. PMID: 10556053.
5. Tetzlaff MT, Bai C, Finegold M, Wilson J, Harper JW, Mahon KA, Elledge SJ. Cyclin F disruption compromises placental development and affects normal cell cycle execution. *Mol Cell Biol* 24(6):2487-98, 3/2004. PMID: PMC355860.
6. Tetzlaff MT, Yu W, Li M, Zhang P, Finegold M, Mahon K, Harper JW, Schwartz RJ, Elledge SJ. Defective cardiovascular development and elevated cyclin E and Notch proteins in mice lacking the Fbw7 F-box protein. *Proc Natl Acad Sci U S A* 101(10):3338-45, 3/2004. e-Pub 2/2004. PMID: PMC373463.
7. Tetzlaff MT, Teh BS, Timme TL, Fujita T, Satoh T, Tabata K, Mai WY, Vlachaki MT, Amato RJ, Kadmon D, Miles BJ, Ayala G, Wheeler TM, Aguilar-Cordova E, Thompson TC, Butler EB. Expanding the therapeutic index of radiation therapy by combining in situ gene therapy in the treatment of prostate cancer. *Technol Cancer Res Treat* 5(1):23-36, 2/2006. PMID: 16417399.
8. Tetzlaff MT, LiVolsi V, Baloch ZW. Assessing the utility of a mutational assay for B-RAF as an adjunct to conventional fine needle aspiration of the thyroid gland. *Adv Anat Pathol* 13(5):228-37, 9/2006. PMID: 16998316.

9. Tetzlaff MT, Liu A, Xu X, Master SR, Baldwin DA, Tobias JW, Livolsi VA, Baloch ZW. Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues. *Endocr Pathol* 18(3):163-73, 2007. PMID: 18058265.
10. Tetzlaff MT, Liu P, O'Malley BW, LiVolsi VA, Elder D. Report of a case of sinonasal undifferentiated carcinoma arising in a background of extensive nasal gliomatosis. *Head Neck* 30(4):549-55, 4/2008. PMID: 17972313.
11. Li JM*, Tetzlaff MT*, Elledge SJ. *Co-first author. Identification of MSA1, a cell cycle-regulated, dosage suppressor of drc1/sld2 and dpb11 mutants. *Cell Cycle* 7(21):3388-98, 11/2008. e-Pub 11/2008. PMID: 18948746.
12. Tetzlaff MT, Xu X, Elder DE, Elenitsas R. Angiomatoid Spitz nevus: a clinicopathological study of six cases and a review of the literature. *J Cutan Pathol* 36(4):471-6, 4/2009. PMID: 19278435.
13. Liu A*, Tetzlaff MT*, Vanbelle P, Elder D, Feldman M, Tobias JW, Sepulveda AR, Xu X. *Co-first author. MicroRNA expression profiling outperforms mRNA expression profiling in formalin-fixed paraffin-embedded tissues. *Int J Clin Exp Pathol* 2(6):519-27, 2009. e-Pub 3/2009. PMCID: PMC2713447.
14. Oza V, Treat J, Cook N, Tetzlaff MT, Yan A. Subcutaneous fat necrosis as a complication of whole-body cooling for birth asphyxia. *Arch Dermatol* 146(8):882-5, 8/2010. PMID: 20713821.
15. Hamilton KW, Abt PL, Rosenbach MA, Bleicher MB, Levine MS, Mehta J, Montgomery SP, Hasz RD, Bono BR, Tetzlaff MT, Mildiner-Early S, Introcaso CE, Blumberg EA. Donor-Derived Strongyloides stercoralis Infections in Renal Transplant Recipients. *Transplantation* 9(19):1019-24, 5/2011. e-Pub 2/2011. PMID: 21358367.
16. Tetzlaff MT, Evans K, DeHoratius DM, Weiss R, Cotsarelis G, Elenitsas R. Fox-fordyce disease following axillary laser hair removal. *Arch Dermatol* 147(5):573-6, 5/2011. PMID: 21576577.
17. Nguyen J, Tetzlaff MT, Zhang PJ, Xu X, Hexner E, Rosenbach M. Fluorescent in situ hybridization of a skin biopsy: An adjunctive tool to support a diagnosis of graft-versus-host disease. *J Am Acad Dermatol* 64(6):e113-4, 6/2011. PMID: 21571154.
18. Tetzlaff MT, Nosek C, Kovarik CL. Epstein-Barr virus-associated leiomyosarcoma with cutaneous involvement in an African child with human immunodeficiency virus: a case report and review of the literature. *J Cutan Pathol* 38(9):731-9, 9/2011. e-Pub 5/2011. PMID: 21623869.
19. Curry JL, Falchook GS, Torres-Cabala CA, Tetzlaff MT, Prieto VG. Resistant mechanisms to BRAF inhibitor PLX4032 in melanoma. *Expert Review of Dermatology* 6(4):355-357, <http://dx.doi.org/10.1586/edm.11.38>, 8/2011.
20. Liu S*, Tetzlaff MT*, Liu A, Liegl-Atzwanger B, Guo J, Xu X. * Co-first author. Loss of microRNA-205 expression is associated with melanoma progression. *Lab Invest* 92(7):1084-96, 7/2012. e-Pub 4/2012. PMID: 22525428.
21. Rose CL, Chakravarti N, Curry JL, Torres-Cabala CA, Bassett R, Prieto VG, Tetzlaff MT. The utility of ATF3 in distinguishing cutaneous squamous cell carcinoma among other cutaneous epithelial neoplasms. *J Cutan Pathol* 39(8):762-8, 8/2012. e-Pub 7/2012. PMID: 22764884.

22. Nicholson KM, Patel KP, Duvic M, Prieto VG, Tetzlaff MT. Bi-clonal, multifocal primary cutaneous marginal zone B cell lymphoma: report of a case and review of the literature. *J Cutan Pathol* 39(9):866-71, 9/2012. e-Pub 7/2012. PMID: 22809282.
23. Liu S*, Tetzlaff MT*, Cui R, Xu X. * Co-first author. miR-200c inhibits melanoma progression and drug resistance through down-regulation of Bmi-1. *Am J Pathol* 181(5):1823-1835, 11/2012. e-Pub 9/2012. PMCID: PMC3483804.
24. Curry JL, Torres-Cabala CA, Tetzlaff MT, Bowman C, Prieto VG. Molecular platforms utilized to detect BRAF V600E mutation in melanoma. *Semin Cutan Med Surg* 31(4):267-73, 12/2012. PMID: 23174497.
25. Curry JL, Falchook GS, Hwu WJ, Torres-Cabala CA, Duvic M, Tetzlaff MT, Prieto VG. Changes in Tumor Morphology and Cyclin-Dependent Kinase Inhibitor Expression in Metastatic Melanoma Treated With Selective Second-Generation BRAF Inhibitor. *Am J Dermatopathol* 35(1):125-8, 2/2013. e-Pub 8/2012. PMID: 22878367.
26. Tetzlaff MT, Curry JL, Ivan D, Wang WL, Torres-Cabala CA, Bassett RL, Valencia KM, McLemore MS, Ross MI, Prieto VG. Immunodetection of phosphohistone H3 as a surrogate of mitotic figure count and clinical outcome in cutaneous melanoma. *Mod Pathol* 26(9):1153-60, 9/2013. e-Pub 4/2013. PMID: 23558574.
27. Tetzlaff MT, Wang WL, Milless TL, Curry JL, Torres-Cabala CA, McLemore MS, Ivan D, Bassett RL, Prieto VG. Ambiguous Melanocytic Tumors In A Tertiary Referral Center: The Contribution Of Fluorescence In Situ Hybridization (FISH) To Conventional Histopathologic And Immunophenotypic Analyses. *Am J Surg Pathol* 37(12):1783-96, 12/2013. PMID: 24061523.
28. Chu VH, Tetzlaff MT, Torres-Cabala CA, Prieto VG, Bassett R Jr, Gershenwald JE, McLemore MS, Ivan D, Wang WL, Ross MI, Curry JL. Impact of the 2009 (7th edition) AJCC melanoma staging system in the classification of thin cutaneous melanomas. *Biomed Res Int.* 898719, 2013, 2013.
29. McQuitty E, Curry JL, Tetzlaff MT, Prieto VG, Duvic M, Torres-Cabala C. The differential diagnosis of CD8-positive ("type D") lymphomatoid papulosis. *J Cutan Pathol* 41(2):88-100, 2/2014. e-Pub 10/2013. PMID: 24118002.
30. Curry JL, Torres-Cabala CA, Kim KB, Tetzlaff MT, Duvic M, Tsai KY, Hong DS, Prieto VG. Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. *Int J Dermatol* 53(3):376-84, 3/2014. e-Pub 7/2013. PMID: 23879247.
31. Pattanaprichakul P, Tetzlaff MT, Lapolla WJ, Torres-Cabala CA, Duvic M, Prieto VG, Tsai KY, Curry JL. Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma. *J Cutan Pathol* 41(3):326-28, 3/2014. e-Pub 12/2013. PMID: 24372055.
32. Loghavi S, Curry JL, Torres-Cabala CA, Ivan D, Patel KP, Mehrotra M, Bassett R, Prieto VG, Tetzlaff MT. Melanoma arising in association with blue nevus: a clinical and pathologic study of 24 cases and comprehensive review of the literature. *Mod Pathol.* e-Pub 4/2014. PMID: 24743221.
33. Schram AM, Kim B, Carlos C, Tetzlaff MT, Schuster M, Rosenbach M. Primary Cutaneous *Candida tropicalis* Infection in a Patient With B-Cell Lymphoma. *Cutis* 93(4):204-206., 4/2014. PMID: 24818181.

34. Yin VT, Wiraszka TA, Tetzlaff M, Curry JL, Esmaeli B. Cutaneous Eyelid Neoplasms as a Toxicity of Vemurafenib Therapy. *Ophthal Plast Reconstr Surg*. e-Pub 5/2014. PMID: 24833447.
35. Chen G, Chakravarti N, Aardalen K, Lazar AJ, Tetzlaff M, Wubberhorst B, Kim SB, Kopetz S, Ledoux A, Vashisht Gopal YN, Goncalves Pereira C, Deng W, Lee JS, Nathanson KL, Aldape KD, Prieto VG, Stuart D, Davies MA. Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target. *Clin Cancer Res*. e-Pub 5/2014. PMID: 24803579.
36. De la Garza Bravo MM, Curry JL, Torres-Cabala CA, Ivan DS, Drucker C, Prieto VG, Tetzlaff MT. Pigmented extramammary Paget disease of the thigh mimicking a melanocytic tumor: report of a case and review of the literature. *J Cutan Pathol* 41(6):529-35, 6/2014. e-Pub 4/2014. PMID: 24698435.
37. Vin H, Talpur R, Tetzlaff MT, Duvic M. T-Cell Receptor- γ in Gamma-Delta Phenotype Cutaneous T-Cell Lymphoma Can Be Accompanied by Atypical Expression of CD30, CD4, or TCR β F1 and an Indolent Clinical Course. *Clin Lymphoma Myeloma Leuk*. e-Pub 6/2014. PMID: 25088535.
38. Curry JL, Tetzlaff MT, Nicholson K, Duvic M, Kim KB, Tsai KY, Hwu WJ, Hong DS, Prieto VG, Torres-Cabala CA. Histological features associated with vemurafenib-induced skin toxicities: examination of 141 cutaneous lesions biopsied during therapy. *Am J Dermatopathol* 36(7):557-61, 7/2014. PMID: 24950418.
39. El-Sawy T, Bakhoun MF, Tetzlaff MT, Nasser QJ, Prieto VG, Ivan D, Sniegowski MC, Yin VT, Pan C, Durairaj V, Esmaeli B. Primary orbital melanoma in association with cellular blue nevus. *Digit J Ophthalmol*. 20(3):35-40, 7/2014.
40. Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff MT, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MA. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. *J Invest Dermatol*. e-Pub 8/2014. PMID: 25148578.
41. Bucheit AD, Chen G, Siroy AE, Tetzlaff MT, Broaddus RR, Milton DR, Fox P, Hwu P, Gershenwald JE, Lazar AJ, Davies MA. Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. *Clin Cancer Res*. e-Pub 8/2014. PMID: 25165098.
42. Henderson SA, Torres-Cabala CA, Curry JL, Bassett RL, Ivan D, Prieto VG, Tetzlaff MT. p40 is more specific than p63 for the distinction of atypical fibroxanthoma from other cutaneous spindle cell malignancies. *Am J Surg Pathol* 38(8):1102-1110, 8/2014. PMID: 25029117.
43. Henderson S, Tetzlaff MT, Pattanaprichakul P, Fox P, Torres-Cabala C, Bassett R, Prieto V, Richards H, Curry J. Detection of mitotic figures and G2+ tumor nuclei with histone markers correlates with worse overall survival in patients with Merkel cell carcinoma. *J Cutan Pathol*. e-Pub 9/2014. PMID: 25263506.
44. Morrissey K, Rosenbach M, DeHoratius D, Elenitsas R, Tetzlaff MT,. Granulomatous changes associated with pigmented purpuric dermatosis. *Cutis* 94(4):197-202, 10/2014. PMID: 25372255.

45. Cachia D, Singh C, Tetzlaff MT, Penas-Prado M. Middle cerebral artery territory infarct due to Cryptococcus infection: An uncommon indication for cerebrospinal fluid analysis in stroke patients. *Diagn Cytopathol.* e-Pub 10/2014. PMID: 25352313.
46. Pickering CR, Zhou JH, Lee JJ, Drummond JA, Peng SA, Saade RE, Tsai KY, Curry J, Tetzlaff MT, Lai SY, Yu J, Muzny DM, Doddapaneni H, Shinbrot E, Covington KR, Zhang J, Seth S, Caulin C, Clayman GL, El-Naggar AK, Gibbs RA, Weber RS, Myers JN, Wheeler DA, Frederick MJ. Mutational landscape of aggressive cutaneous squamous cell carcinoma. *Clin Cancer Res.* e-Pub 10/2014. PMID: 25303977.
47. Ramani NS, Curry JL, Kapil J, Rapini RP, Tetzlaff MT, Prieto VG, Torres-Cabala CA. Panniculitis With Necrotizing Granulomata in a Patient on BRAF Inhibitor (Dabrafenib) Therapy for Metastatic Melanoma. *Am J Dermatopathol.* e-Pub 11/2014. PMID: 25839886.
48. de la Garza Bravo MM, Patel KP, Loghavi S, Curry JL, Torres Cabala CA, Cason RC, Gangar P, Prieto VG, Medeiros LJ, Duvic M, Tetzlaff MT. Shared Clonality in Distinctive Lesions of Lymphomatoid Papulosis and Mycosis Fungoides Occurring in the Same Patients Suggests a Common Origin. *Hum Pathol.* e-Pub 12/2014. PMID: 25666664.
49. Martz CA, Ottina KA, Singleton KR, Jasper JS, Wardell SE, Peraza-Penton A, Anderson GR, Winter PS, Wang T, Alley HM, Kwong LN, Cooper ZA, Tetzlaff MT, Chen PL, Rathmell JC, Flaherty KT, Wargo JA, McDonnell DP, Sabatini DM, Wood KC. Systematic identification of signaling pathways with potential to confer anticancer drug resistance. *Sci Signal* 7(357):ra121, 2014. e-Pub 12/2014. PMID: 25538079.
50. Torres-Cabala CA, Curry JL, Li Ning Tapia EM, Ramos C, Tetzlaff MT, Prieto VG, Miranda RN, Bravo F. HTLV-1-associated infective dermatitis demonstrates low frequency of FOXP3-positive T-regulatory lymphocytes. *J Dermatol Sci.* e-Pub 1/2015. PMID: 25676425.
51. Wang WL, Torres-Cabala C, Curry J, Ivan D, McLemore M, Tetzlaff MT, Zembowicz A, Prieto VG, Lazar AJ. Metastatic Atypical Fibroxanthoma: A Series of 11 Cases Including With Minimal and No Subcutaneous Involvement. *Am J Dermatopathol.* e-Pub 1/2015. PMID: 25590287.
52. Litvinov IV, Tetzlaff MT, Rahme E, Habel Y, Risser DR, Gangar P, Jennings MA, Pehr K, Prieto VG, Sasseville D, Duvic M. Identification of geographic clustering and regions spared by cutaneous T-cell lymphoma in Texas using 2 distinct cancer registries. *Cancer.* e-Pub 2/2015. PMID: 25728286.
53. Stockman DL, Curry JL, Torres-Cabala CA, Watson IR, Siroy AE, Bassett RL, Zou L, Patel KP, Luthra R, Davies MA, Wargo JA, Routbort MA, Broaddus RR, Prieto VG, Lazar AJ, Tetzlaff MT. Use of Clinical Next-Generation Sequencing To Identify Melanomas Harboring SMARCB1 Mutations. *J Cutan Pathol.* e-Pub 3/2015. PMID: 25754356.
54. Liu S*, Tetzlaff MT*, Wang T*, Yang R, Xie L, Zhang G, Krepler C, Xiao M, Beqiri M, Xu W, Karakousis G, Schuchter L, Amaravadi RK, Xu W, Wei Z, Herlyn M, Yao Y, Zhang L, Wang Y, Zhang L, Xu X. *Co-First author. miR-200c/Bmi1 Axis and Epithelial-Mesenchymal Transition Contribute to Acquired Resistance to BRAF Inhibitor Treatment. *Pigment Cell Melanoma Res.* e-Pub 4/2015. PMID: 25903073.
55. Wang C, Tetzlaff MT, Hick R, Duvic M. Reed syndrome presenting with leiomyosarcoma. *JAAD Case Reports* 1(3):150-2, 2015 May 25, 5/2015.

56. Tetzlaff MT, Pattanaprichakul P, Wargo J, Fox PP, Patel KP, Estrella JS, Broaddus RR, Williams MD, Davies MA, Routbort MJ, Lazar AJ, Woodman SE, Hwu WJ, Gershenwald JE, Prieto VG, Torres-Cabala CA, Curry JL. Utility of BRAF V600E immunohistochemical expression pattern as a surrogate of BRAF mutation status in 154 patients with advanced melanoma. *Hum Pathol.* e-Pub 5/2015. PMID: 26058727.
57. Al-Shamsi HO, Kee BK, Tetzlaff MT, Wolff RA. Capecitabine-induced leukocytoclastic vasculitis under neoadjuvant chemotherapy for locally advanced colorectal cancer. *J Gastrointest Oncol* 6(3):E40-3, 6/2015. PMID: 26029464.
58. Litvinov IV, Tetzlaff MT, Rahme E, Jennings MA, Risser DR, Gangar P, Netchiporouk E, Moreau L, Prieto VG, Sasseville D, Duvic M. Demographic patterns of Cutaneous T-Cell Lymphoma incidence in Texas based on two different cancer registries. *Cancer Med.* e-Pub 7/2015. PMID: 26136403.
59. Tetzlaff MT*, Curry JL*, Yin V, Pattanaprichakul P, Manonukul J, Uiprasertkul M, Manyam GC, Wani KM, Aldape K, Zhang L, Prieto VG, Esmali B. *Indicates co-first author. Distinct Pathways in the Pathogenesis of Sebaceous Carcinomas Implicated by Differentially Expressed MicroRNAs. *JAMA Ophthalmol.* e-Pub 7/2015. PMID: 26203913.
60. Duvic M, Tetzlaff MT, Gangar P, Clos AL, Sui D, Talpur R. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. *J Clin Oncol.* e-Pub 8/2015. PMID: 26261247.
61. Danialan R, Tetzlaff MT, Torres-Cabala CA, Mays SR, Prieto VG, Bell D, Curry JL. Cutaneous metastasis from anaplastic thyroid carcinoma exhibiting exclusively a spindle cell morphology. A case report and review of literature. *J Cutan Pathol.* e-Pub 9/2015. PMID: 26347145.
62. Estrella JS, Tetzlaff MT, Bassett RL, Patel KP, Williams MD, Curry J, Rashid A, Hamilton SR, Broaddus RR. Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing. *Mol Cancer Ther.* e-Pub 10/2015. PMID: 26438153.
63. Kheir WJ, Tetzlaff MT, Pfeiffer ML, Mulay K, Ozgur O, Morrell G, Esmali B. Epithelial, non-melanocytic and melanocytic proliferations of the ocular surface. *Semin Diagn Pathol.* e-Pub 10/2015. PMID: 27021909.
64. Talpur R, Chockalingam R, Wang C, Tetzlaff MT, Duvic M. A Single-Center Experience With Brentuximab Vedotin in Gamma Delta T-Cell Lymphoma. *Clin Lymphoma Myeloma Leuk.* e-Pub 12/2015. PMID: 26705678.
65. Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li H, Kwong LN, Heffernan TP, Hu J, Bassett RL, Bosenberg MW, Woodman SE, Overwijk WW, Lizee G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi LG, Davies MA, Hwu P. Loss of PTEN promotes resistance to T-cell mediated immunotherapy. *Cancer Discov.* e-Pub 12/2015. PMID: 26645196.
66. Feldmeyer L, Tetzlaff MT, Fox P, Nagarajan P, Curry J, Ivan D, Torres Cabala CA, Prieto VG, Aung PP. Prognostic Implication of Lymphovascular Invasion Detected by Double Immunostaining for D2-40 and MITF1 in Primary Cutaneous Melanoma. *Am J Dermatopathol.* e-Pub 12/2015. PMID: 26675354.

67. Tetzlaff MT, Torres-Cabala CA, Pattanaprichakul P, Rapini RP, Prieto VG, Curry JL. Emerging clinical applications of selected biomarkers in melanoma. *Clin Cosmet Investig Dermatol* 8:35-46, 2015. e-Pub 1/2015. PMID: PMC4321413.
68. Mauzo SH, Ferrarotto R, Bell D, Torres-Cabala CA, Tetzlaff MT, Prieto VG, Aung PP. Molecular characteristics and potential therapeutic targets in Merkel cell carcinoma. *J Clin Pathol*. e-Pub 1/2016. PMID: 26818033.
69. Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. *Oncoimmunology* 5(3):e1136044, 3/2016. e-Pub 2/2016. PMID: 27141370.
70. Feldmeyer L, Prieto VG, Ivan D, Nagarajan P, Tetzlaff MT, Curry JL, Bell D, Moon BS, Torres-Cabala CA, Aung PP. Role of Radiotherapy in Aggressive Digital Papillary Adenocarcinoma. *Ann Clin Lab Sci* 46(2):222-4, 3/2016. PMID: 27098633.
71. Jour G, Glitza IC, Ellis RM, Torres-Cabala CA, Tetzlaff MT, Li JY, Nagarajan P, Huen A, Aung PP, Ivan D, Drucker CR, Prieto VG, Rapini RP, Patel A, Curry JL. Autoimmune Dermatologic Toxicities from Immune Checkpoint Blockade with anti-PD-1 Antibody Therapy: A Report on Bullous Skin Eruptions. *J Cutan Pathol*. e-Pub 4/2016. PMID: 27086658.
72. Mudaliar K, Tetzlaff MT, Duvic M, Ciurea A, Hymes S, Milton DR, Tsai KY, Prieto VG, Torres-Cabala CA, Curry JL. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression. *Hum Pathol* 50:79-89, 4/2016. e-Pub 12/2015. PMID: 26997441.
73. Chen G, McQuade JL, Panka DJ, Hudgens CW, Amin-Mansour A, Mu XJ, Bahl S, Jané-Valbuena J, Wani KM, Reuben A, Creasy CA, Jiang H, Cooper ZA, Roszik J, Bassett RL, Joon AY, Simpson LM, Mouton RD, Glitza IC, Patel SP, Hwu WJ, Amaria RN, Diab A, Hwu P, Lazar AJ, Wargo JA, Garraway LA, Tetzlaff MT, Sullivan RJ, Kim KB, Davies MA. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. *JAMA Oncol*. e-Pub 4/2016. PMID: 27124486.
74. Ravishankar S, Nagarajan P, Curry JL, Tetzlaff MT, Ivan D, Torres-Cabala CA, Aung PP, Prieto VG. Giemsa is the optimal counterstain for immunohistochemical detection of BRAF V600E mutation status in pigmented melanomas. *J Cutan Pathol*. e-Pub 4/2016. PMID: 27124588.
75. Kaur A, Webster MR, Marchbank K, Behera R, Ndoeye A, Kugel CH, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. *Nature*. e-Pub 4/2016. PMID: 27042933.

76. Feldmeyer L, Hudgens CW, Lyons GR, Nagarajan P, Aung PP, Curry JL, Torres Cabala CA, Mino B, Rodriguez-Canales J, Reuben A, Chen PL, Ko JS, Billings SD, Bassett RL, Wistuba II, Cooper ZA, Prieto VG, Wargo JA, Tetzlaff MT. Density, distribution, and composition of immune infiltrates correlate with survival in Merkel cell carcinoma. *Clin Cancer Res.* e-Pub 5/2016. PMID: 27166398.
77. Napoli M, Venkatanarayan A, Raulji P, Meyers BA, Norton W, Mangala LS, Sood AK, Rodriguez-Aguayo C, Lopez-Berestein G, Vin H, Duvic M, Tetzlaff MT, Curry JL, Rook AH, Abbas HA, Coarfa C, Gunaratne PH, Tsai KY, Flores ER. ?Np63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer. *Cancer Cell* 29(6):874-88, 6/2016. PMCID: PMC4908836.
78. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, Petaccia De Macedo M, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. *Cancer Discov.* e-Pub 6/2016. PMID: 27301722.
79. Al-Rohil RN, Curry JL, Torres-Cabala CA, Nagarajan P, Ivan D, Aung PP, Ray GF, Bassett RL, Prieto VG, Tetzlaff MT. Proliferation indices correlate with diagnosis and metastasis in diagnostically challenging melanocytic tumors. *Hum Pathol* 53:73-81, 7/2016. e-Pub 3/2016. PMID: 27004944.
80. Minca EC, Al-Rohil RN, Wang M, Harms PW, Ko JS, Collie AM, Kovalyshyn I, Prieto VG, Tetzlaff MT, Billings SD, Andea AA. Comparison between melanoma gene expression score and fluorescence in-situ hybridization for the classification of melanocytic lesions. *Mod Pathol* 29(8):832-43, 8/2016. e-Pub 5/2016. PMID: 27174586.
81. Wieser I, Tetzlaff MT, Torres Cabala CA, Duvic M. Primary cutaneous CD30(+) lymphoproliferative disorders. *J Dtsch Dermatol Ges* 14(8):767-82, 8/2016. PMID: 27509411.
82. Kaur A, Webster MR, Marchbank K, Behera R, Ndoeye A, Kugel CH, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT. Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. *Nature* 537(7619):254, 9/2016. e-Pub 7/2016. PMID: 27383789.
83. Aung PP, Rady PL, Nagarajan P, Ivan D, Tetzlaff MT, Curry JL, Tying SK, Prieto VG, Torres-Cabala CA. Detection of Merkel Cell Polyoma Virus and Beta Human Papillomavirus in Multiple Eccrine Poromas in a Patient With Acute Leukemia Treated With Stem Cell Transplant. *Am J Dermatopathol.* e-Pub 9/2016. PMID: 27655121.
84. Dai J, Tetzlaff MT, Schuchter LM, Elder DE, Elenitsas R. Histopathologic and mutational analysis of a case of blue nevus-like melanoma. *J Cutan Pathol* 43(9):776-80, 9/2016. e-Pub 6/2016. PMID: 27152652.

85. Erstine EM, Tetzlaff MT, Ko JS, Prieto VG, Cheah AL, Billings SD. Living on the Edge: Diagnosing Sarcomatoid Melanoma Using Histopathologic Cues at the Edge of a Dedifferentiated Tumor: A Report of 2 Cases and Review of the Literature. *Am J Dermatopathol*. e-Pub 9/2016. PMID: 27655123.
86. Tetzlaff MT, Singh RR, Seviour EG, Curry JL, Hudgens CW, Bell D, Wimmer DA, Ning J, Czerniak BA, Zhang L, Davies MA, Prieto VG, Broaddus RR, Ram P, Luthra R, Esmali B. Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma. *J Pathol* 240(1):84-95, 9/2016. e-Pub 6/2016. PMID: 27287813.
87. Pina-Oviedo S, Torres-Cabala CA, Miranda RN, Tetzlaff MT, Singh S, Rapini RP, Prieto VG, Aung PP. Concomitant Cutaneous Langerhans Cell Histiocytosis and Leukemia Cutis. *Am J Dermatopathol*. e-Pub 10/2016. PMID: 27759701.
88. Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Chen K, Forget MA, Haymaker CL, Chen JQ, Meric-Bernstam F, Eterovic AK, Shaw KR, Mills GB, Gershenwald JE, Radvanyi LG, Hwu P, Futreal PA, Gibbons DL, Lazar AJ, Bernatchez C, Davies MA, Woodman SE. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. *BMC Med* 14(1):168, 10/2016. e-Pub 10/2016. PMCID: PMC5078889.
89. Ramani NS, Curry JL, Merrill ED, Aung PP, Prieto V, Tetzlaff MT, Duvic M, Miranda R, Torres-Cabala C. Primary Cutaneous Gamma-Delta (γ/δ) T-cell Lymphoma: An Unusual Case With Very Subtle Histopathological Findings. *Am J Dermatopathol* 38(10):e147-9, 10/2016. e-Pub 8/2016. PMID: 27533072.
90. Pandey P, Al-Rohil RN, Goldstein JB, Tetzlaff MT, Barnes TG, Baldwin SE, Fogelman D, Abraham SC, Piha-Paul SA. Cutaneous Metastasis of a Mucoepidermoid Carcinoma of the Pancreas: First Reported Case. *Am J Dermatopathol* 38(11):852-856, 11/2016. e-Pub 3/2016. PMID: 27043340.
91. Nagarajan P, Curry JL, Ning J, Piao J, Torres Cabala CA, Aung PP, Ivan D, Ross MI, Levenback CF, Frumovitz M, Gershenwald JE, Davies MA, Malpica A, Prieto V, Tetzlaff MT. Tumor thickness and mitotic rate robustly predict melanoma-specific survival in patients with primary vulvar melanoma: A retrospective review of 100 cases. *Clin Cancer Res*. e-Pub 11/2016. PMID: 27864417.
92. Kim DW, Haydu LE, Joon AY, Bassett RL, Siroy AE, Tetzlaff MT, Routbort MJ, Amaria RN, Wargo JA, McQuade JL, Kemnade J, Hwu P, Woodman SE, Roszik J, Kim KB, Gershenwald JE, Lazar AJ, Davies MA. Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients. *Cancer*. e-Pub 12/2016. PMID: 27911979.
93. Honarpisheh HH, Curry JL, Richards K, Nagarajan P, Aung PP, Torres-Cabala CA, Ivan D, Drucker CR, Cartun R, Prieto VG, Tetzlaff MT. Cutaneous histoplasmosis with prominent parasitization of epidermal keratinocytes: Report of a case. *J Cutan Pathol* 43(12):1155-1160, 12/2016. e-Pub 9/2016. PMID: 27516534.
94. Al-Rohil RN, Torres-Cabala CA, Patel A, Tetzlaff MT, Ivan D, Nagarajan P, Curry JL, Miranda RN, Duvic M, Prieto VG, Aung PP. Loss of CD30 expression after treatment with Brentuximab Vedotin in a patient with Anaplastic Large Cell Lymphoma: a novel finding. *J Cutan Pathol* 43(12):1161-1166, 12/2016. e-Pub 9/2016. PMID: 27531242.

95. Uemura M, Faisal F, Haymaker C, McQuail N, Sirmans E, Hudgens CW, Barbara L, Bernatchez C, Curry JL, Hwu P, Tetzlaff MT, Diab A. A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1. *J Immunother Cancer* 4(55):55, 2016. e-Pub 9/2016. PMID: PMC5028978.
96. Siroy AE, Aung PP, Torres-Cabala CA, Tetzlaff MT, Nagarajan P, Milton DR, Curry JL, Ivan D, Prieto VG. Clinical Significance of BRAF V600E Mutational Status in Capsular Nevi of Sentinel Lymph Nodes in Patients with Primary Cutaneous Melanoma. *Hum Pathol* 59:48-54, 1/2017. e-Pub 9/2016. PMID: 27666765.
97. Konopinski J, Prieto VG, Ivan D, Nagarajan P, Tetzlaff MT, Curry JL, Torres-Cabala CA, Fuller GN, Aung PP. Isolated Ectopic Cutaneous Atypical Meningioma of the Scalp: Another Mimicker of Primary Adnexal Tumor. *Am J Dermatopathol*. e-Pub 1/2017. PMID: 28178009.
98. Guitart J, Martinez-Escala ME, Subtil A, Duvic M, Pulitzer MP, Olsen EA, Kim E, Rook AH, Samimi SS, Wood GS, Girardi M, Junkins-Hopkins J, Ivan DS, Selim MA, Sable KA, Virmani P, Pincus LB, Tetzlaff MT, Kim J, Kim YH. Primary Cutaneous Aggressive Epidermotropic Cytotoxic T-cell Lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas. *Mod Pathol*. e-Pub 1/2017. PMID: 28128277.
99. Nagarajan P, Tetzlaff MT, Curry JL, Prieto VG. Use of New Techniques in Addition to IHC Applied to the Diagnosis of Melanocytic Lesions, With Emphasis on CGH, FISH, and Mass Spectrometry. *Actas Dermosifiliogr* 16(1):17-30, Jan - Feb, 1/2017. e-Pub 6/2016. PMID: 27344067.
100. Curry JL, Tetzlaff MT, Nagarajan P, Drucker C, Diab A, Hymes SR, Duvic M, Hwu WJ, Wargo JA, Torres-Cabala CA, Rapini RP, Prieto VG. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. *J Cutan Pathol* 44(2):158-176, 2/2017. e-Pub 12/2016. PMID: 27859479.
101. Chakravarti N, Ivan D, Trinh VA, Glitza IC, Curry JL, Torres-Cabala C, Tetzlaff MT, Bassett RL, Prieto VG, Hwu WJ. High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients. *Melanoma Res* 27(1):24-31, 2/2017. e-Pub 10/2016. PMID: 27768639.
102. Agbay RL, Torres-Cabala CA, Patel KP, Merrill ED, Duvic M, Quesada A, Prieto VG, Aung PP, Loghavi S, Young KH, Hu S, Ferrufino-Schmidt MC, Tetzlaff MT, Li S, Medeiros LJ, Miranda RN. Immunophenotypic Shifts in Primary Cutaneous $\gamma\delta$ T-Cell Lymphoma Suggest Antigenic Modulation: A Study of Sequential Biopsy Specimens. *Am J Surg Pathol*. e-Pub 2/2017. PMID: 28248813.
103. Shustef E, Torres-Cabala CA, Curry JL, Tetzlaff MT, Nagarajan P, Ivan D, Prieto VG, Aung PP. Intraepithelial Melanoma in the Stomach After Treatment With Immune Checkpoint Blockade Therapy. *Am J Dermatopathol*. e-Pub 2/2017. PMID: 28248716.
104. Tetzlaff MT, Nagarajan P, Chon S, Huen A, Diab A, Omar P, Aung PP, Torres-Cabala CA, Mays SR, Prieto VG, Curry JL. Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features. *Am J Dermatopathol* 39(2):121-129, 2/2017. PMID: 28134729.
105. Haymaker CL, Kim D, Uemura M, Vence LM, Phillip A, McQuail N, Brown PD, Fernandez I, Hudgens CW, Creasy C, Hwu WJ, Sharma P, Tetzlaff MT, Allison JP, Hwu P, Bernatchez C, Diab A. Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion

- after Whole Brain Radiation and PD-1 Blockade. *Cancer Immunol Res* 5(2):100-105, 2/2017. e-Pub 1/2017. PMID: 28062513.
106. Merrill ED, Agbay R, Miranda RN, Aung PP, Tetzlaff MT, Young KH, Curry JL, Nagarajan P, Ivan D, Prieto VG, Medeiros LJ, Duvic M, Torres-Cabala CA. Primary Cutaneous T-Cell Lymphomas Showing Gamma-Delta ($\gamma\delta$) Phenotype and Predominantly Epidermotropic Pattern are Clinicopathologically Distinct From Classic Primary Cutaneous $\gamma\delta$ T-Cell Lymphomas. *Am J Surg Pathol* 41(2):204-215, 2/2017. e-Pub 11/2016. PMID: 27879514.
 107. Minca EC, Billings SD, Elson P, Tetzlaff MT, Andea AA, Ko JS. Significance of Epidermal Mitoses in Challenging Melanocytic Proliferations. *J Cutan Pathol* 44(2):135-143, 2/2017. e-Pub 12/2016. PMID: 27862191.
 108. Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. *Sci Transl Med* 9(379), 3/2017. PMID: 28251903.
 109. Ramani N, Aung PP, Hwu WJ, Nagarajan P, Tetzlaff MT, Curry JL, Ivan D, Prieto VG, Torres-Cabala CA. Aberrant Expression of FLI-1 in Melanoma. *J Cutan Pathol*. e-Pub 6/2017. PMID: 28605142.
 110. Valero-Torres A, Prieto VG, Nagarajan P, Torres-Cabala CA, Tetzlaff MT, Curry JL, Ivan D, Aung PP. Metastatic Melanoma With Papillary Features: A Mimic and Possible Diagnostic Pitfall. *Am J Dermatopathol* 39(6):468-470, 6/2017. PMID: 28525424.
 111. Agarwal A, Gopinath A, Tetzlaff MT, Prieto VG. Phosphohistone-H3 and Ki67: Useful Markers in Differentiating Dermatofibroma From Dermatofibrosarcoma Protuberans and Atypical Fibrohistiocytic Lesions. *Am J Dermatopathol* 39(7):504-507, 7/2017. PMID: 28609344.
 112. Lewis DJ, Vin H, Hinojosa T, Tetzlaff MT, Dabaja BS, Duvic M. Primary Cutaneous Peripheral T-Cell Lymphoma in a Sporotrichoid Pattern: A Case Report. *J Cutan Med Surg*:1203475417721425. e-Pub 7/2017. PMID: 28712310.
 113. Saenz-Ibarra B, Prieto VG, Torres-Cabala CA, Huen A, Nagarajan P, Tetzlaff MT, Curry JL, Ivan D, Aung PP. Coccidioidomycosis Involving Lungs and Skin: A Mimicker of Metastatic Disease. *Am J Dermatopathol*. e-Pub 8/2017. PMID: 28857979.
 114. Loghavi S, Curry JL, Garcia-Manero G, Patel KP, Xu J, Khoury JD, Torres-Cabala CA, Nagarajan P, Aung PP, Gibson BR, Goodwin BP, Kelly BC, Korivi BR, Medeiros LJ, Prieto VG, Kantarjian HM, Bueso-Ramos CE, and Tetzlaff MT. Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: expanding the spectrum of skin lesions in chronic myelomonocytic leukemia. *J Cutan Pathol*. e-Pub 9/2017. PMID: 28885734.
 115. Jour G, Aung PP, Merrill ED, Curry JL, Tetzlaff MT, Nagarajan P, Ivan D, Prieto VG, Duvic M, Miranda RN, Torres-Cabala CA. Differential expression of CCR4 in primary cutaneous gamma/delta ($\gamma\delta$) T cell lymphomas and mycosis fungoides: Significance for diagnosis and therapy. *J Dermatol Sci*. e-Pub 9/2017. PMID: 29030090.

116. Tetzlaff MT, Jazaeri AA, Torres-Cabala CA, Korivi BR, Landon GA, Nagarajan P, Choksi A, Chen L, Uemura M, Aung PP, Diab A, Sharma P, Davies MA, Amaria R, Prieto VG, Curry JL. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy. Report of two patients. *J Cutan Pathol.* e-Pub 9/2017. PMID: 28901560.
117. Somasundaram R, Wagner S, Zhang G, Perego M, Fukunaga-Kalabis M, Wagner C, Hristova D, Garg K, Hards R, Wei Z, Wu L, Frederick D, Flaherty K, Scolyer RA, Long G, Maurer M, Krepler C, Damle M, Ellingsworth C, Grinman L, Dunagin M, Raj A, Scholler N, Gross L, Beqiri M, Liu Q, Bennett K, Griss J, Schaider H, Czerniecki B, Schuchter L, Herlyn D, Herlyn M, Xu X, Tian T, Zhang J, Hudgens C, Chen G, Tetzlaff MT, Choi H, Watson I, Davies MA, Wargo J, Hafner C, Mayerhoefer M, Karanikas G, Jalili A, Bauer-Pohl V, Weihsengruber F, Rappersberger K, Koller J, and Lang R. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. *Nature Communications* 8(1):607, 9/2017.
118. Tetzlaff MT, Reuben A, Billings SD, Prieto VG, Curry JL. Toward a Molecular-Genetic Classification of Spitzoid Neoplasms. *Clin Lab Med* 37(3):431-448, 9/2017. PMID: 28802494.
119. Yam C, Xu X, Davies MA, Gimotty PA, Morrisette JJ, Tetzlaff MT, Wani K, Liu S, Deng W, Buckley M, Zhao J, Amaravadi RK, Haas N, Kudchadkar RR, Pavlick A, Sosman JA, Tawbi H, Walker L, Schuchter LM, Karakousis GC, Gangadhar TC. A multicenter phase I study evaluating dual PI3K and BRAF inhibition with PX-866 and vemurafenib in patients with advanced BRAF V600 mutant solid tumors. *Clin Cancer Res.* e-Pub 10/2017. PMID: 29051322.
120. Lewis DJ, Talpur R, Huen AO, Tetzlaff MT, and Duvic M. Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results. *JAMA Dermatol.* e-Pub 10/2017. PMID: 28980004.
121. Mahajan KR, Ko JS, Tetzlaff MT, Hudgens CW, Billings SD and Cohen JA. Merkel cell carcinoma with fingolimod treatment for multiple sclerosis: A case report. *Multiple sclerosis and related disorders*:12-14, 10/2017.
122. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Sloane RS, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Sanchez EMR, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. *Science.* e-Pub 11/2017. PMID: 29097493.
123. Mauzo SM, Tetzlaff MT, Nelson K, Amaria R, Patel S, Aung PP, Nagarajan P, Torres-Cabala CA, Diab A, Prieto VG and Curry JL. Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade. *International Journal of Dermatology* 10.1111:ijd.13833., 11/2017.

124. Liu S, Tetzlaff MT, Wang T, Chen X, Yang R, Kumar S, Vultur A, Li P, Martin J, Herlyn M, Amaravadi RK, Li B, and Xu X. Hypoxia-Activated Prodrug Enhances Therapeutic Effect of Sunitinib in Melanoma. *Oncotarget* 8(70):115140-115152., 12/2017.
125. Thakar SD, Sagiv O, Tetzlaff MT, El-Naggar A, Debnam JM, Kandl TJ, Esmaeli B. A 60-year-old woman with an asymptomatic left lacrimal gland mass found incidentally. *Digit J Ophthalmol* 23(4):27-29, 2017. e-Pub 10/2017. PMID: PMC5791630.
126. Reuben A, Petaccia de Macedo M, McQuade J, Joon A, Ren Z, Calderone T, Conner B, Wani K, Cooper ZA, Tawbi H, Tetzlaff MT, Padera RF, Durand JB, Lazar AJ, Wargo JA, Davies MA. Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. *Oncoimmunology* 6(12):e1361097, 2017. e-Pub 8/2017. PMID: PMC5706622.
127. Uemura M, Fa'ak F, Haymaker C, McQuail N, Sirmans E, Hudgens CW, Barbara L, Bernatchez C, Curry JL, Hwu P, Tetzlaff MT, Diab A. Erratum to: A case report of Grover's disease from immunotherapy—a skin toxicity induced by inhibition of CTLA-4 but not PD-1. *J Immunother Cancer* 5:7, 2017. e-Pub 1/2017. PMID: PMC5244590.
128. Litvinov IV, Tetzlaff MT, Thibault P, Gangar P, Moreau L, Watters AK, Netchiporouk E, Pehr K, Prieto VG, Rahme E, Provost N, Gilbert M, Sasseville D, Duvic M. Gene expression analysis in Cutaneous T-Cell Lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicators. *Oncoimmunology* 6(5):e1306618, 2017. e-Pub 3/2017. PMID: PMC5468001.
129. Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. *NPJ Genom Med* 2, 2017. e-Pub 4/2017. PMID: PMC5557036.
130. Qin Y, Petaccia de Macedo M, Reuben A, Forget MA, Haymaker C, Bernatchez C, Spencer CN, Gopalakrishnan V, Reddy S, Cooper ZA, Fulbright OJ, Ramachandran R, Wahl A, Flores E, Thorsen ST, Tavera RJ, Conrad C, Williams MD, Tetzlaff MT, Wang WL, Gombos DS, Esmaeli B, Amaria RN, Hwu P, Wargo JA, Lazar AJ, Patel SP. Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. *Oncoimmunology* 6(6):e1321187, 2017. e-Pub 5/2017. PMID: PMC5486182.
131. Lefrançois P, Tetzlaff MT, Moreau L, Watters AK, Netchiporouk E, Provost N, Gilbert M, Ni X, Sasseville D, Duvic M, Litvinov IV. TruSeq-Based Gene Expression Analysis of Formalin-Fixed Paraffin-Embedded (FFPE) Cutaneous T-Cell Lymphoma Samples: Subgroup Analysis Results and Elucidation of Biases from FFPE Sample Processing on the TruSeq Platform. *Front Med (Lausanne)* 4:153, 2017. e-Pub 9/2017. PMID: PMC5614967.
132. Sagiv O, Thakar SD, Morrell G, Tetzlaff MT, and Esmaeli B. Rituximab Monotherapy Is Effective in Treating Orbital Necrobiotic Xanthogranuloma. *Ophthalm Plast Reconstr Surg* 34(1):e24-e27, 2018 Jan/Feb, 1/2018. PMID: 28863117.

133. Tetzlaff MT. Immunohistochemical markers informing the diagnosis of sebaceous carcinoma and its distinction from its mimics: Adipophilin and Factor XIIIa to the rescue? *Journal of Cutaneous Pathology* 45(1):29-32, 1/2018.
134. Tetzlaff MT, Nelson K, Diab A, Staerkel G, Nagarajan P, Torres-Cabala CA, Chasen B, Wargo J, Prieto VG, Amaria R and Curry JL. Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. *J Immunother Cancer* 6(1):14, 2/2018.
135. Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. *Lancet Oncol* 19(2):181-193, 2/2018. e-Pub 1/2018. PMID: 29361468.
136. Tetzlaff MT. Immunohistochemical markers informing the diagnosis of sebaceous carcinoma and its distinction from its mimics: Adipophilin and Factor XIIIa to the rescue? *Journal of Cutaneous Pathology* 45(1):29-32, 1/2018.
137. Lewis DJ, Miranda RN, Oh CW, Hinojosa T, Medeiros LJ, Curry JL, Tetzlaff MT, Torres-Cabala CA, Nagarajan P, Ravandi-Kashani F, Duvic M. Pruritic arthropod bite-like papules in T-cell large granular lymphocytic leukaemia and chronic myelomonocytic leukaemia. *Clin Exp Dermatol*. e-Pub 2/2018. PMID: 29423961.
138. Thakar S, Kandl T, Sagiv O, Tripathy D, Tetzlaff MT, Kapur S, Myers J, Hwu WJ, Esmali BE. Desmoplastic Melanoma of the Periorbital Region. *Ophthalmic Plastic and Reconstructive Surgery* 34(2):e48-e52, 2018 Mar/Apr, 3/2018.
139. Mauzo SH, Milton DR, Prieto VG, Torres-Cabala CA, Wang WL, Chakravarti N, Nagarajan P, Tetzlaff MT, Curry JL, Ivan D, Brown RE, Aung PP. Summary of expression of SPARC protein in cutaneous vascular neoplasms and mimickers. *Ann Diagn Pathol* 34:151-154. e-Pub 3/2018. PMID: 29660567.
140. Gru AA, Kim J, Pulitzer M, Guitart J, Battistella M, Wood GS, Cerroni L, Kempf W, Willemze R, Pawade J, Querfeld C, Schaffer A, Pincus L, Tetzlaff MT, Duvic M, Scarisbrick J, Porcu P, Mangold AR, Dicaudio DJ, Shinohara M, Hong EK, Horton B, Kim YH. The Use of Central Pathology Review With Digital Slide Scanning in Advanced-stage Mycosis Fungoides and Sézary Syndrome: A Multi-institutional and International Pathology Study. *Am J Surg Pathol*. e-Pub 3/2018. PMID: 29543675.
141. Tetzlaff MT, Nagarajan P. Update on Merkel Cell Carcinoma. *Head Neck Pathol* 12(1):31-43, 3/2018. PMID: 29556962.
142. Trinidad C, Nelson KC, Glitza Oliva IC, Torres-Cabala CA, Nagarajan P, Tetzlaff MT, Ivan D, Hwu WJ, Prieto VG, Curry JL, Aung PP. Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern. *J Cutan Pathol*. e-Pub 4/2018. PMID: 29633300.
143. Dolkar T, Trinidad CM, Nelson KC, Amaria RN, Nagarajan P, Torres-Cabala CA, Ivan D, Prieto VG, Tetzlaff MT, Curry JL, Aung PP. Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: A detailed examination of the clinicopathologic features. *J Cutan Pathol*. e-Pub 4/2018. PMID: 29665030.

144. Farah M, Nagarajan P, Torres-Cabala CA, Curry JL, Amaria RN, Wargo J, Tawbi H, Ivan D, Prieto VG, Tetzlaff MT, Aung PP. Metastatic melanoma with balloon/histiocytoid cytomorphology after treatment with immunotherapy: A histologic mimic and diagnostic pitfall. *J Cutan Pathol*. e-Pub 4/2018. PMID: 29672900.
145. Curry JL, Tetzlaff MT, Wang SA, Landon G, Alouch N, Patel SP, Nagarajan P, Gupta S, Aung PP, Devine CE, Khoury JD, Loghavi S, Prieto VG, DiNardo CD, Gershenwald JE. Case Report of Myeloid Sarcoma Masquerading as In-Transit Metastasis at a Previous Melanoma Site: Avoiding a Diagnostic Pitfall. *Am J Dermatopathol*. e-Pub 6/2018. PMID: 29863571.
146. Farah M, Nagarajan P, Curry JL, Tang Z, Kim TB, Aung PP, Torres-Cabala CA, Eterovic AK, Wargo JA, Prieto VG, Tetzlaff MT. Spitzoid melanoma with histopathological features of ALK gene rearrangement exhibiting ALK copy number gain: a novel mechanism of ALK activation in spitzoid neoplasia. *Br J Dermatol*. e-Pub 6/2018. PMID: 29897634.
147. Chen WS, Tetzlaff MT, Diwan H, Jahan-Tigh R, Diab A, Nelson K, Glitza IC, Kaunitz GJ, Johnson D, Torres-Cabala C, Pacha O, Taube JM, Maloney K, Prieto VG, Curry JL. Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions. *J Cutan Pathol*. e-Pub 6/2018. PMID: 29943453.
148. Arudra K, Patel R, Tetzlaff MT, Hymes S, Subbiah V, Meric-Bernstam F, Torres-Cabala C, Aung PP, Nagarajan P, Diab A, Prieto VG, Nelson K, Curry JL. Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. *J Cutan Pathol*. e-Pub 7/2018. PMID: 30021048.
149. Al-Rohil RN, Milton DR, Nagarajan P, Curry JL, Feldmeyer L, Torres-Cabala CA, Ivan D, Prieto VG, Tetzlaff MT, and Aung PP. Intratumoral and Peritumoral Lymphovascular Invasion Detected by D2-40 Immunohistochemistry Correlates with Metastasis in Primary Cutaneous Merkel Cell Carcinoma. *Human Pathology* 77:98-107, 7/2018.
150. Vishnoi M, Boral D, Liu H, Sprouse ML, Yin W, Goswami-Sewell D, Tetzlaff MT, Davies MA, Glitza Oliva IC, Marchetti D. Targeting USP7 identifies a metastasis-competent state within bone marrow-resident melanoma CTCs. *Cancer Res*. e-Pub 7/2018. PMID: 30026332.
151. Seto AG, Beatty X, Lynch JM, Hermreck M, Tetzlaff MT, Duvic M, Jackson AL. Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. *Br J Haematol*. e-Pub 8/2018. PMID: 30125933.
152. Tetzlaff MT, Messina J, Stein JE, Xu X, Amaria RN, Blank C, Van De Wiel B, Ferguson PM, Rawson RV, Ross MI, Spillane AJ, Gershenwald JE, Saw RPM, Mitchell T, Menzies AM, Long GV, Wargo JA, Davies MA, Prieto VG, Taube JM and Scolyer RA. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. *Annals of Oncology* 29(8):1861-1868., 8/2018.
153. Sa HS, Rubin ML, Xu S, Ning J, Tetzlaff MT, Sagiv O, Kandl TJ, Esmaeli B. Prognostic factors for local recurrence, metastasis and survival for sebaceous carcinoma of the eyelid: observations in 100 patients. *Br J Ophthalmol*. e-Pub 8/2018. PMID: 30131380.
154. Ronen S, Ivan D, Torres-Cabala CA, Curry JL, Tetzlaff MT, Aung PP, Nagarajan P, Suster S, Prieto VG. Post-Radiation Vascular Lesions of the Breast. *J Cutan Pathol*. e-Pub 9/2018. PMID: 30251277.

155. Adam L, San Lucas FA, Fowler J, Yu Y, Wu W, Liu Y, Wang H, Menter DG, Tetzlaff MT, Ensor JE, Manyam G, Arold ST, Huff CD, Kopetz S, Scheet P, Overman MJ. DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway. *Clin Cancer Res.* e-Pub 10/2018. PMID: 30352910.
156. Crumley S, Kurnit K, Hudgens C, Fellman B, Tetzlaff MT, Broaddus R. Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes. *Mod Pathol.* e-Pub 10/2018. PMID: 30291344.
157. Konopinski JC, Danialan R, Torres-Cabala CA, Tetzlaff MT, Nagarajan P, Curry JL, Ivan D, Prieto VG, Aung PP. Melanoma coexisting with solar elastosis: a potential pitfall in the differential diagnosis between nevus and melanoma. *Hum Pathol.* e-Pub 10/2018. PMID: 30359637.
158. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT*, Wargo JA*. *Indicates co-senior authors. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. *Nat Med.* e-Pub 10/2018. PMID: 30297909.
159. Sagiv O, Bell D, Guo Y, Su S, Wester ST, Jiang K, Yin VT, Shinder R, Hayek B, Kim HJ, Tetzlaff MT, Esmaeli B. Pathological Features and Clinical Course in Patients With Recurrent or Malignant Orbital Solitary Fibrous Tumor/Hemangiopericytoma. *Ophthalmic Plast Reconstr Surg.* e-Pub 10/2018. PMID: 30371551.
160. Kaur A, Ecker BL, Douglass SM, Kugel CH III, Webster MR, Almeida F, Somasundaram R, Hayden J, Ban E, Ahmadzadeh H, Franco-Barraza J, Shah N, Mellis I, Keeney F, Kossenkov AV, Tang HY, Yin X, Liu Q, Xu X, Fane M, Brafford P, Herlyn M, Speicher DW, Wargo JA, Tetzlaff MT, Haydu L, Raj A, Cukierman E, Shenoy VB, and Weeraratna AT. Remodeling of the collagen matrix in aging skin promotes melanoma metastasis, and affects immune cell motility. *Cancer Discovery,* 10/2018.
161. Fedda F, Migden MR, Curry JL, Torres-Cabala CA, Tetzlaff MT, Aung PP, Prieto VG, Ivan D, Myers JN, Nagarajan P. ANGIOTROPISM IN RECURRENT CUTANEOUS SQUAMOUS CELL CARCINOMA: IMPLICATIONS FOR REGIONAL TUMOR RECURRENCE AND EXTRAVASCULAR MIGRATORY SPREAD. *J Cutan Pathol.* e-Pub 11/2018. PMID: 30414196.
162. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. *Nat Med* 24(12):1941, 12/2018. PMID: 30361510.
163. Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR. Fecal microbiota transplantation for refractory immune

- checkpoint inhibitor-associated colitis. *Nat Med* 24(12):1804-1808, 12/2018. e-Pub 11/2018. PMID: PMC6322556.
164. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. *Nat Med* 24(12):1942, 12/2018. PMID: 30361511.
 165. Lefrançois P, Xie P, Wang L, Tetzlaff MT, Moreau L, Watters AK, Netchiporouk E, Provost N, Gilbert M, Ni X, Sasseville D, Wheeler DA, Duvic M, Litvinov IV. Gene expression profiling and immune cell-type deconvolution highlight robust disease progression and survival markers in multiple cohorts of CTCL patients. *Oncoimmunology* 7(8):e1467856, 2018. e-Pub 5/2018. PMID: PMC6136868.
 166. Kandl TJ, Sagiv O, Curry JL, Ning J, Ma J, Hudgens CW, Van Arnam J, Wargo JA, Esmali B, Tetzlaff MT. High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma. *Oncoimmunology* 7(9):e1475874, 2018. e-Pub 7/2018. PMID: PMC6140585.
 167. Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR. Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. *Nat Med* 25(1):188, 1/2019. PMID: 30479380.
 168. Blando J, Sharma A, Higa MG, Zhao H, Vence L, Yadav SS, Kim J, Sepulveda AM, Sharp M, Maitra A, Wargo J, Tetzlaff MT, Broaddus R, Katz MHG, Varadhachary GR, Overman M, Wang H, Yee C, Bernatchez C, Iacobuzio-Donahue C, Basu S, Allison JP, Sharma P. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. *Proc Natl Acad Sci U S A*. e-Pub 1/2019. PMID: 30635425.
 169. Aung PP, Parra ER, Barua S, Sui D, Ning J, Mino B, Ledesma DA, Curry JL, Nagarajan P, Torres Cabala CA, Efstathiou E, Hoang A, Wong MKK, Wargo JA, Lazar AJ, Rao A, Prieto VG, Wistuba II, Tetzlaff MT. B7-H3 expression in Merkel cell carcinoma-associated endothelial cells correlates with locally aggressive primary tumor features and increased vascular density. *Clin Cancer Res*. e-Pub 2/2019. PMID: 30808776.
 170. Tetzlaff MT, Curry JL, Ning J, Sagiv O, Kandl TL, Peng B, Bell D, Routbort M, Hudgens CW, Ivan D, Kim TB, Chen K, Eterovic AK, Shaw K, Prieto VG, Yemelyanova A, Esmali B. Distinct biological types of ocular adnexal sebaceous carcinoma: HPV-driven and virus-negative tumors arise through non-overlapping molecular-genetic alterations. *Clin Cancer Res* 25(4):1280-1290, 2/2019. e-Pub 11/2018. PMID: 30420449.
 171. Curry JL, Reuben A, Szczepaniak-Sloane R, Jing N, Milton DR, Lee CH, Hudgens C, George S, Torres-Cabala C, Johnson D, Subramanya S, Wargo JA, Mudaliar K, Wistuba II, Prieto VG, Diab A, Tetzlaff MT. Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14+ and CD16+ monocytes driving an innate immune response. *J Cutan Pathol*. e-Pub 3/2019. PMID: 30883858.

172. Aung PP, Nagarajan P, Tetzlaff MT, Curry JL, Tang G, Abdullaev Z, Pack SD, Ivan D, Prieto VG, Torres-Cabala CA. Melanoma With Loss of BAP1 Expression in Patients With No Family History of BAP1-Associated Cancer Susceptibility Syndrome: A Case Series. *Am J Dermatopathol* 41(3):167-179, 3/2019. PMID: 30801340.
173. Sa HS, Tetzlaff MT, Esmaeli B. Predictors of Local Recurrence for Eyelid Sebaceous Carcinoma: Questionable Value of Routine Conjunctival Map Biopsies for Detection of Pagetoid Spread. *Ophthalmic Plast Reconstr Surg*. e-Pub 3/2019. PMID: 30865067.
174. Ferguson SD, Bindal S, Bassett RL, Haydu LE, McCutcheon IE, Heimberger AB, Li J, O'Brien BJ, Guha-Thakurta N, Tetzlaff MT, Tawbi H, Davies MA, Glitza IC. Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD). *J Neurooncol*. e-Pub 3/2019. PMID: 30847840.
175. Xu S, Sagiv O, Rubin ML, Sa HS, Tetzlaff MT, Nagarajan P, Ning J, Esmaeli B. Validation Study of the AJCC Cancer Staging Manual, Eighth Edition, Staging System for Eyelid and Periocular Squamous Cell Carcinoma. *JAMA Ophthalmol*. e-Pub 3/2019. PMID: 30869769.
176. Bentebibel SE, Hurwitz ME, Bernatchez C, Haymaker C, Hudgens CW, Kluger HM, Tetzlaff MT, Tagliaferri MA, Zalevsky J, Hoch U, Fanton C, Aung S, Hwu P, Curti BD, Tannir NM, Sznol M, Diab A. A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL-2-Receptor Beta/Gamma ($\beta\gamma$)-Biased Cytokine, in Patients With Advanced or Metastatic Solid Tumors. *Cancer Discov*. e-Pub 4/2019. PMID: 30988166.
177. Johnson DH, Patel AB, Uemura MI, Trinh VA, Jackson N, Zobniw CM, Tetzlaff MT, Hwu P, Curry JL, Diab A. IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy. *Cancer Immunol Res*. e-Pub 4/2019. PMID: 30996018.
178. Mauzo SH, Tetzlaff MT, Milton DR, Siroy AE, Nagarajan P, Torres-Cabala CA, Ivan D, Curry JL, Hudgens CW, Wargo JA, Sahin AA, Pettaway CA, Prieto VG, Aung PP. Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy. *Cancers (Basel)* 11(6), 5/2019. e-Pub 5/2019. PMID: PMC6627796.
179. Nagarajan P, El-Hadad C, Gruschus SK, Ning J, Hudgens CW, Sagiv O, Gross N, Tetzlaff MT, Esmaeli B. PD-L1/PD-1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma. *Invest Ophthalmol Vis Sci* 60(6):2388-2398, 5/2019. PMID: PMC6890426.
180. Reddy SM, Reuben A, Barua S, Jiang H, Zhang S, Wang L, Gopalakrishnan V, Hudgens CW, Tetzlaff MT, Reuben JM, Tsujikawa T, Coussens LM, Wani K, He Y, Villarreal L, Wood AL, Rao A, Woodward WA, Ueno NT, Krishnamurthy S, Wargo JA, Mittendorf EA. Poor response to neoadjuvant chemotherapy correlates with mast cell infiltration in inflammatory breast cancer. *Cancer Immunol Res*. e-Pub 5/2019. PMID: 31043414.
181. Erstine EM, Tetzlaff MT, Jia X, Aung PP, Prieto VG, Funchain P, Gastman BR, Billings SD, Ko JS. Prognostic Significance of "Nonsolid" Microscopic Metastasis in Merkel Cell Carcinoma Sentinel Lymph Nodes. *Am J Surg Pathol*. e-Pub 5/2019. PMID: 31094923.
182. Tetzlaff MT, Tang S, Duke T, Grabell DA, Cabanillas ME, Zuo Z, Yao JC, Nagarajan P, Aung PP, Torres-Cabala CA, Duvic M, Prieto VG, Huen A, Curry JL. Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis fungoides-like morphologic and molecular features. *J Cutan Pathol*. e-Pub 6/2019. PMID: 31254410.

183. Mejbil HA, Nelson KC, Pradhan D, Ivan D, Zaleski M, Nagarajan P, Tetzlaff MT, Curry JL, Torres-Cabala CA, Prieto VG, Aung PP. Cutaneous neoplasms composed of melanoma and carcinoma: A rare but important diagnostic pitfall and review of the literature. *J Cutan Pathol*. e-Pub 7/2019. PMID: 31361351.
184. Amaria RN*, Menzies AM*, Burton EM*, Scolyer RA*, Tetzlaff MT*, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA, International Neoadjuvant Melanoma Consortium members, Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. *Lancet Oncol* 20(7):e378-e389, 7/2019. PMID: 31267972.
185. Veeranki OL, Tong Z, Dokey R, Mejia A, Zhang J, Qiao Y, Singh PK, Katkhuda R, Mino B, Tailor R, Canales JR, Bassett R, Ajani J, Wu JY, Kopetz S, Blum M, Hofstetter W, Tetzlaff MT, Krishnan S, Lin SH, Maru D. Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma. *Oncotarget* 10(45):4703-4718, 7/2019. e-Pub 7/2019. PMCID: PMC6659793.
186. Yildiz P, Aung PP, Milton DR, Hruska C, Ivan D, Nagarajan P, Tetzlaff MT, Curry JL, Torres-Cabala C, Prieto VG. Measurement of Tumor Thickness in Cutaneous Squamous Cell Carcinomas: Do the Different Methods Provide Better Prognostic Data? *Am J Dermatopathol*. e-Pub 8/2019. PMID: 31464719.
187. Nagarajan P, Piao J, Ning J, Noordenbos LE, Curry JL, Torres-Cabala CA, Diwan AH, Ivan D, Aung PP, Ross MI, Royal RE, Wargo JA, Wang WL, Samdani R, Lazar AJ, Rashid A, Davies MA, Prieto VG, Gershenwald JE, Tetzlaff MT. Prognostic Model for Patient Survival in Primary Anorectal Mucosal Melanoma: Stage at Presentation Determines Relevance of Histopathologic Features. *Mod Pathol*. e-Pub 8/2019. PMID: 31383963.
188. Namikawa K, Aung PP, Milton DR, Tetzlaff MT, Torres Cabala CA, Curry JL, Nagarajan P, Ivan D, Ross MI, Gershenwald JE, Prieto VG. Correlation of tumor burden in sentinel lymph nodes with tumor burden in non-sentinel lymph nodes and survival in cutaneous melanoma. *Clin Cancer Res*. e-Pub 9/2019. PMID: 31570567.
189. Vashisht Gopal YN, Gammon S, Prasad R, Knighton B, Pisaneschi F, Roszik J, Feng N, Johnson S, Pramanik S, Sudderth J, Sui D, Hudgens C, Fischer GM, Deng W, Reuben A, Peng W, Wang J, McQuade JL, Tetzlaff MT, Di Francesco ME, Marszalek J, Piwnicka-Worms D, DeBerardinis RJ, Davies MA. A novel mitochondrial inhibitor blocks MAPK pathway and overcomes MAPK inhibitor-resistance in melanoma. *Clin Cancer Res* 25(21):6429-6442, 11/2019. e-Pub 8/2019. PMCID: PMC6825560.
190. Mejbil HA, Arudra SKC, Pradhan D, Torres-Cabala CA, Nagarajan P, Tetzlaff MT, Curry JL, Ivan D, Duose DY, Luthra R, Prieto VG, Ballester LY, Aung PP. Immunohistochemical and Molecular Features of Melanomas Exhibiting Intratumor and Intertumor Histomorphologic Heterogeneity. *Cancers (Basel)* 11(11), 11/2019. e-Pub 11/2019. PMCID: PMC6896082.
191. Pradhan D, Jour G, Milton D, Vasudevaraja V, Tetzlaff MT, Nagarajan P, Curry JL, Ivan D, Long L, Ding Y, Ezhilarasan R, Sulman EP, Diab A, Hwu WJ, Prieto VG, Torres-Cabala CA, Aung PP. Aberrant DNA Methylation Predicts Melanoma-Specific Survival in Patients

- with Acral Melanoma. *Cancers (Basel)* 11(12), 12/2019. e-Pub 12/2019. PMID: PMC6966546.
192. Devins KM, Tetzlaff MT, Baloch Z, LiVolsi VA. The evolving landscape of HPV-related neoplasia in the head and neck. *Hum Pathol* 94:29-39, 12/2019. e-Pub 10/2019. PMID: 31654690.
 193. Ruiz SJ, Al Salihi S, Prieto VG, Nagarajan P, Tetzlaff MT, Curry JL, Ivan D, Torres-Cabala CA, Aung PP. Unusual cutaneous metastatic carcinoma. *Ann Diagn Pathol* 43:151399, 12/2019. e-Pub 8/2019. PMID: 31675677.
 194. Tandon N, Hudgens C, Fellman B, Tetzlaff MT, Broaddus RR. Variable Expression of MSH6 in Endometrial Carcinomas With Intact Mismatch Repair and With MLH1 Loss Due to MLH1 Methylation. *Int J Gynecol Pathol*. e-Pub 12/2019. PMID: 31855955.
 195. Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, Gopalakrishnan V, Xi Y, Zhao H, Amaria RN, Tawbi HA, Cogdill AP, Liu W, LeBleu VS, Kugeratski FG, Patel S, Davies MA, Hwu P, Lee JE, Gershenwald JE, Lucci A, Arora R, Woodman S, Keung EZ, Gaudreau PO, Reuben A, Spencer CN, Burton EM, Haydu LE, Lazar AJ, Zapassodi R, Hudgens CW, Ledesma DA, Ong S, Bailey M, Warren S, Rao D, Krijgsman O, Rozeman EA, Peeper D, Blank CU, Schumacher TN, Butterfield LH, Zelazowska MA, McBride KM, Kalluri R, Allison J, Petitprez F, Fridman WH, Sautès-Fridman C, Hacohen N, Rezvani K, Sharma P*, Tetzlaff MT*, Wang L*, Wargo JA*. B cells and tertiary lymphoid structures promote immunotherapy response. *Nature* 577(7791):549-555, 1/2020. e-Pub 1/2020. PMID: 31942075 *Shared senior authorship..
 196. Tetzlaff MT, and Farah M. Without missing a beat: Absence of cilia informs the diagnosis of histopathologically challenging Spitzoid melanocytic neoplasms. *Journal of Investigative Dermatology*. In Press.
 197. Tetzlaff MT, Harms PW. Danger is only skin deep: aggressive epidermal carcinomas. An overview of the diagnosis, demographics, molecular-genetics, staging, prognostic biomarkers, and therapeutic advances in Merkel cell carcinoma. *Mod Pathol* 33(Suppl 1):42-55, 1/2020. e-Pub 11/2019. PMID: 31676786.
 198. Haydu LE, Lo SN, McQuade JL, Amaria RN, Wargo J, Ross MI, Cormier JN, Lucci A, Lee JE, Ferguson SD, Saw RPM, Spillane AJ, Shannon KF, Stretch JR, Hwu P, Patel SP, Diab A, Wong MKK, Glitza Oliva IC, Tawbi H, Carlino MS, Menzies AM, Long GV, Lazar AJ, Tetzlaff MT, Scolyer RA, Gershenwald JE, Thompson JF, Davies MA. Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. *J Clin Oncol*:JCO1901508. e-Pub 1/2020. PMID: 31990608.
 199. Farah M, Nelson KC, Tetzlaff MT, Nagarajan P, Torres-Cabala CA, Prieto VG, Curry JL, Aung PP. Lichen planus related to transforming growth factor beta inhibitor in a patient with metastatic chondrosarcoma: a case report. *J Cutan Pathol*. e-Pub 1/2020. PMID: 31930527.
 200. Parra ER, Jiang M, Solis L, Mino B, Laberiano C, Hernandez S, Gite S, Verma A, Tetzlaff M, Haymaker C, Tamegnon A, Rodriguez-Canales J, Hoyd C, Bernachez C, Wistuba I. Procedural Requirements and Recommendations for Multiplex Immunofluorescence Tyramide Signal Amplification Assays to Support Translational Oncology Studies. *Cancers (Basel)* 12(2), 1/2020. e-Pub 1/2020. PMID: 31972974.

201. Xu S, Moss TJ, Laura Rubin M, Ning J, Eterovic K, Yu H, Jia R, Fan X, Tetzlaff MT, Esmali B. Whole-exome sequencing for ocular adnexal sebaceous carcinoma suggests PCDH15 as a novel mutation associated with metastasis. *Mod Pathol.* e-Pub 1/2020. PMID: 31937901.
202. Sa HS, Rubin ML, Ning J, Li W, Tetzlaff MT, McGovern SL, Paulino AC, Herzog CE, Gill JB, Esmali B. Association of T and N Categories of the American Joint Commission on Cancer, 8th Edition, With Metastasis and Survival in Patients With Orbital Sarcoma. *JAMA Ophthalmol.* e-Pub 2/2020. PMID: PMC7047857.
203. Duncan LM, Tetzlaff MT. BAP1-inactivated melanocytic tumor with preserved BAP1 expression? Morphology to the rescue! *J Cutan Pathol.* e-Pub 2/2020. PMID: 32096236.
204. Yang RK, Qing Y, Jelloul FZ, Routbort MJ, Wang P, Shaw K, Zhang J, Lee J, Medeiros LJ, Kopetz S, Tetzlaff MT, Broaddus RR. Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies. *Oncotarget* 11(6):600-618, 2/2020. e-Pub 2/2020. PMID: PMC7021232.
205. Francisco-Cruz A, Parra ER, Tetzlaff MT, Wistuba II. Multiplex Immunofluorescence Assays. *Methods Mol Biol* 2055:467-495, 2020. PMID: 31502166.
206. Kwong LN, Petaccia De Macedo M, Haydu L, Joon AY, Tetzlaff MT, Calderone TL, Wu CJ, Kwong MK, Rozik J, Hess K, Davies MA, Lazar AJ, and Gershenwald JE. Biological Validation of RNA Sequencing Data from Formalin-Fixed Paraffin-Embedded Primary Melanomas. *JCO Precision Oncology.* In Press.
207. Esmali B, Rubin ML, Xu S, Goepfert DR, Curry JL, Prieto VG, Ning J, and Tetzlaff MT. Greater Tumor Thickness, Ulceration, and Positive Sentinel Lymph Node Are Associated with Worse Prognosis in Patients with Conjunctival Melanoma: Implications for Future AJCC Classifications. *American Journal of Surgical Pathology.* In Press.
208. Fischer GM, Jalali A, Kircher DA, Lee WC, McQuade JL, Haydu LE, Joon AY, Reuben A, de Macedo MP, L. Carapeto FC, Yang C, Srivastava A, Ambati CR, Sreekumar A, Hudgens CW, Knighton B, Deng W, Ferguson SD, Tawbi HA, Glitza IC, Gershenwald JE, Gopal YNV, Hwu P, Huse JT, Wargo JA, Futreal PA, Putluri N, Lazar AJ, DeBerardinis RJ, Marszalek JR, Zhang J, Holmen SL, Tetzlaff MT, and Davies MA. Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. *Cancer Discovery.* In Press.
209. Liu B, Li L, Yang G, Geng C, Luo Y, Wu W, Manyam G, Korentzelos D, Park S, Tang Z, Wu C, Dong Z, Sigouros M, Sboner A, Beltran H, Chen Y, Corn P, Tetzlaff MT, Troncso P, Broom BM, and Thompson TC. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. *Clinical Cancer Research.* In Press.
210. Farah M, Reuben A, Spassova I, Yang RK, Kubat L, Nagarajan P, Ning J, Li W, Aung PP, Curry JL, Torres-Cabala CA, Hudgens CW, Ugurel S, Schadendorf D, Han G, Gumbs C, Little LD, Futreal A, Wistuba II, Prieto VG, Wang L, Wong MK, Wargo JA, Becker JC and Tetzlaff MT. T cell repertoire in combination with T cell density predicts clinical outcomes in patients with Merkel cell carcinoma. *J Invest Dermatol.* 2020 Apr 15:S0022-202X(20)31355-5. doi: 10.1016/j.jid.2020.02.031.
211. Duncan LM and Tetzlaff MT,. BAP-1 Inactivated Melanocytic Tumor with preserved BAP-1 expression? Morphology to the rescue! *Journal of Cutaneous Pathology.* In Press.

212. Mitra A, Andrews MC, Roh W, De Macedo MP, Hudgens CW, Carapeto F, Singh S, Reuben A, Wang F, Mao X, Song X, Wani K, Tippen S, Ng KS, Schalck A, Sakellariou-Thompson DA, Chen E, Reddy SM, Spencer CN, Wiesnoski D, Little LD, Gumbs C, Cooper ZA, Burton EM, Hwu P, Davies MA, Zhang J, Bernatchez C, Navin N, Sharma P, Allison JP, Wargo JA, Yee C, Tetzlaff MT, Hwu WJ, Lazar AJ, Futreal PA. Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. *Nat Commun.* 2020 Apr 15;11(1):1839. doi: 10.1038/s41467-020-15538-9.
213. Chen PL, Neishaboori N, Tetzlaff MT, Chen WS, Aung PP, Curry JL, Nagarajan P, Ivan D, Hwu WJ, Prieto VG, Torres-Cabala CA. BAP-1 Expression Status by Immunohistochemistry in Cellular Blue Nevus and Blue Nevus-like Melanoma. *Am J Dermatopathol.* 2020 May;42(5):313-321.
214. Marques-Piubelli ML, Tetzlaff MT, Nagarajan P, Duke TC, Glitza Oliva IC, Ledesma DA, Aung PP, Torres-Cabala CA, Wistuba II, Prieto VG, Nelson KC, Curry JL. Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma. *J Cutan Pathol.* 2020 May 12. doi: 10.1111/cup.13739.
215. Ramani NS, Aung PP, Gu J, Sfamenos S, Sdringola-Maranga C, Nagarajan P, Tetzlaff MT, Curry JL, Ivan D, Diab A, Prieto VG, Hwu WJ, Torres-Cabala CA. TERT amplification but not activation of canonical Wnt/ β -catenin pathway is involved in acral lentiginous melanoma progression to metastasis. *Mod Pathol.* 2020 May 13. doi: 10.1038/s41379-020-0565-5.
216. Taube JM, Akturk G, Angelo M, Engle EL, Gnjatic S, Greenbaum S, Greenwald NF, Hedvat CV, Hollmann TJ, Juco J, Parra ER, Rebelatto MC, Rimm DL, Rodriguez-Canales J, Schalper KA, Stack EC, Ferreira CS, Korski K, Lako A, Rodig SJ, Schenck E, Steele KE, Surace MJ, Tetzlaff MT, von Loga K, Wistuba II, Bifulco CB; Society for Immunotherapy of Cancer (SITC) Pathology Task Force. The Society for Immunotherapy in Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation. *J Immunother Cancer.* 2020 May;8(1):e000155.

BOOKS AND CHAPTERS

1. Curry JL, Tetzlaff MT, Lazar AJ, Prieto VG. Application of Molecular Pathology to Cutaneous Melanocytic Lesions. In: *Molecular Pathology of Dermatologic Diseases.* Springer Science, 2015.
2. Tetzlaff MT, Curry JL, and Prieto VG. Application of Molecular Pathology to Tissue Identification in Cutaneous Pathology. In: *Molecular Pathology of Dermatologic Diseases.* Springer Science, 2015.
3. Slade A, Tetzlaff MT, Trinh VA, Hwu WJ, Pettaway CA. Primary Urethral Melanoma In Males And Females: A Review. In: *Rare Genitourinary Tumors.* Springer: Switzerland, 2016.
4. Tetzlaff MT. Molecular Studies of Melanocytic Lesions. In: *Applied Immunohistochemistry and Molecular Studies in the Evaluation of Skin Neoplasms.* Springer Science. 2016.

5. Loghavi SL and Tetzlaff MT. Primary cutaneous CD4+ small/medium T-cell lymphoma. In: Hematopathology of the Skin: Clinical & Pathological Approach. Wolters Kluwer Health. 2018.
6. Tetzlaff MT, Chu E, and Curry JL. Dermatologic toxicities to targeted and immune modulatory therapies. Editor: Barnhill. 2020.

OTHER PUBLICATIONS

1. Tetzlaff MT, North J and Esameili BE. Update on Sebaceous Neoplasia: The morphologic spectrum and molecular genetic drivers of sebaceous carcinoma. Diagnostic Histopathology. In Press.

SIGNIFICANT PUBLICATIONS

1. Tetzlaff MT, Singh RR, Seviour EG, Curry JL, Hudgens CW, Bell D, Wimmer DA, Ning J, Czerniak BA, Zhang L, Davies MA, Prieto VG, Broaddus RR, Ram P, Luthra R, Esmali B. Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma. J Pathol 240(1):84-95, 9/2016. e-Pub 6/2016. PMID: 27287813.

Tetzlaff MT, Curry JL, Ning J, Sagiv O, Kandl TL, Peng B, Bell D, Routbort M, Hudgens CW, Ivan D, Kim TB, Chen K, Eterovic AK, Shaw K, Prieto VG, Yemelyanova A, Esmali B. Distinct biological types of ocular adnexal sebaceous carcinoma: HPV-driven and virus-negative tumors arise through non-overlapping molecular-genetic alterations. Clin Cancer Res 25(4):1280-1290, 2/2019. e-Pub 11/2018. PMID: 30420449.

In a series of papers, we showed ocular adnexal sebaceous carcinoma are characterized by: (i) an enrichment in somatically acquired mutations activating the Phosphoinositide 3-kinase (PI3K) pathway and (ii) two biologically distinctive subsets of OASC (Type 1 with TP53, RB1, NOTCH mutations versus Type 2 that are TP53, RB1 and NOTCH wild type but with transcriptionally active high risk HPV subtypes in a subset). I led these efforts and worked with colleagues across the institution from sequencing cores, bioinformatics and oculoplastic surgery.

2. Tetzlaff MT, Messina J, Stein JE, Xu X, Amaria RN, Blank C, Van De Wiel B, Ferguson PM, Rawson RV, Ross MI, Spillane AJ, Gershenwald JE, Saw RPM, Mitchell T, Menzies AM, Long GV, Wargo JA, Davies MA, Prieto VG, Taube JM and Scolyer RA. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. *Annals of Oncology* 29(8):1861-1868., 8/2018.

Amaria RN*, Menzies AM*, Burton EM*, Scolyer RA*, Tetzlaff MT*, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA, International Neoadjuvant Melanoma Consortium members, Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. *Lancet Oncol* 20(7):e378-e389, 7/2019. PMID: 31267972.

I led an international effort that is the pathology 'white paper' for pathologic characterization of resection specimens following neoadjuvant therapy in melanoma, and I was a co-leader of a similar effort to provide the comprehensive 'white paper' for recommendations for medical and surgical oncologists. These combined efforts were a reflection of my role as a leader in The International Neoadjuvant Melanoma Consortium (INMC).

3. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT*, Wargo JA*. *Indicates co-senior authors. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. *Nat Med.* e-Pub 10/2018. PMID: 30297909.

Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. *Lancet Oncol* 19(2):181-193, 2/2018. e-Pub 1/2018. PMID: 29361468.

I led the pathologic characterization of pre-, on- and post-treatment tissues of patients with surgically resectable stage III metastatic melanoma treated with either immune checkpoint blockade or targeted therapy. In particular, I provided a comprehensive assessment of the extent and composition of the pathologic response. I co-led the translational studies in which we performed whole exome DNA and whole transcriptome RNA sequencing on patient samples, and I worked with Nanostring to leverage their digital spatial profiling platform (formerly DSP and now GeoMx) to identify predictive biomarkers from the pre- and post-treatment specimens.

4. Curry JL, Tetzlaff MT, Nagarajan P, Drucker C, Diab A, Hymes SR, Duvic M, Hwu WJ, Wargo JA, Torres-Cabala CA, Rapini RP, Prieto VG. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. *J Cutan Pathol* 44(2):158-176, 2/2017. e-Pub 12/2016. PMID: 27859479.

In collaboration with my colleague Dr. Jonathan Curry, we comprehensively described the spectrum of cutaneous toxicities to immune checkpoint blockade therapy. This was among the first efforts to comprehensively review the spectrum of histopathologic findings encountered in the setting of cutaneous reactions to immune checkpoint blockade. This review article remains among the most frequently downloaded articles from *The Journal of Cutaneous Pathology* and has been widely cited.

5. Feldmeyer L, Hudgens CW, Lyons GR, Nagarajan P, Aung PP, Curry JL, Torres Cabala CA, Mino B, Rodriguez-Canales J, Reuben A, Chen PL, Ko JS, Billings SD, Bassett RL, Wistuba II, Cooper ZA, Prieto VG, Wargo JA, Tetzlaff MT. Density, distribution, and composition of immune infiltrates correlate with survival in Merkel cell carcinoma. *Clin Cancer Res*. e-Pub 5/2016. PMID: 27166398.

Farah M, Reuben A, Spassova I, Yang RK, Kubat L, Nagarajan P, Ning J, Li W, Aung PP, Curry JL, Torres-Cabala CA, Hudgens CW, Ugurel S, Schadendorf D, Gumbs C, Little LD, Futreal A, Wistuba II, Prieto VG, Wang L, Wong MK, Wargo JA, Becker JC, Tetzlaff MT. T cell repertoire in combination with T cell density predicts clinical outcomes in patients with Merkel cell carcinoma. *Journal of Investigative Dermatology*. In press.

Through a series of papers, we first showed that the density, distribution and composition of the tumor associated T cell infiltrate correlates with clinical outcome in Merkel cell carcinoma. Using digital image assisted quantification, we showed specifically that the density of CD8+ T cells along the tumor periphery correlates with patient survival. Next, we performed T cell receptor sequencing and showed that population based metrics of the T cell repertoire (namely, a T cell repertoire that reflects a tumor antigen directed response) correlates with survival. Finally, combining these metrics (Density and T cell repertoire) predicts survival among patients with Merkel cell carcinoma, including those who present with advanced stage.

CONFERENCE ABSTRACTS

1. Tetzlaff MT, Jackle H, Pankratz MJ. A genetic screen for *Drosophila* larvae defective in feeding identifies schluckless, a transcription factor essential for foregut development. International *Drosophila* Research Conference. Atlanta, Georgia, 1995.
2. Tetzlaff MT, Jackle H, Pankratz MJ. Lack of *Drosophila* cytoskeletal tropomyosin affects head morphogenesis during larval development. European *Drosophila* Research Conference Tübingen, Germany, 1995.
3. Tetzlaff MT, Bai C, Finegold M, Wilson J, Harper JW, Mahon KA, Elledge SJ. Cyclin F disruption compromises placental development and affects normal cell cycle execution. Annual Retreat of the Medical Scientist Training Program. Baylor College of Medicine. The Woodlands, Texas, 2002.

4. Tetzlaff MT, Yu W, Li M, Zhang P, Finegold M, Mahon K, Harper JW, Schwartz RJ, Elledge SJ. Defective cardiovascular development and elevated cyclin E and Notch proteins in mice lacking the Fbw7 F-box protein. Annual Retreat of the Medical Scientist Training Program. Baylor College of Medicine. Galveston, Texas, 2003.
5. Tetzlaff MT, Liu A, Tobias JW, Master SR, Xu X, Baldwin DA, LiVolsi VA, Baloch ZW. Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues. *Modern Pathology* 20(2):105A, 3/2007.
6. Tetzlaff MT, Xu X, Elder DE, Elenitsas R. A Case Series of Angiomatoid Spitz Nevus. *The Journal of Cutaneous Pathology* 35(1):168a, 1/2008.
7. Tetzlaff MT, LiVolsi VA, Baloch ZW, Furth EE, and Montone KT. A rapid in situ hybridization technique to identify miRNAs with altered expression in papillary thyroid carcinoma. *Laboratory Investigation* 88(1):111A, 1/2008.
8. Tetzlaff MT, Montone KT, LiVolsi VA and Baloch ZW. Cyclin D1 expression as a marker of papillary thyroid carcinoma. *Modern Pathology* 22:252A, 1/2009.
9. Morrissey KL, Rosenbach MR, Elenitsas RE, Tetzlaff MT. Granulomatous pigmented purpuric dermatosis: report of three cases and a review of the literature. *Journal of Cutaneous Pathology* 38(1):101, 2010.
10. Tetzlaff MT, Nosek C and Kovarik CL. Cutaneous Abdominal Mass in an African child with Human Immunodeficiency Virus: Epstein Barr Virus-Associated Leiomyosarcoma. Report of a case and review of the literature of leiomyosarcomas in HIV-infected children. *Journal of Cutaneous Pathology* 38(1):123, 1/2011.
11. Tetzlaff MT, Evans KE, DeHoratius D, Weiss R, Elenitsas RE. Fox-Fordyce disease in a patient following axillary laser hair removal. *Journal of Cutaneous Pathology* 38(1):102, 1/2011.
12. Wanat K, Tetzlaff MT, Introcaso C, and Rosenbach M. Worms Gone Wild: Disseminated Strongyloides Hyperinfection in a renal transplant recipient. *Journal of Cutaneous Pathology* 38(1):86, 1/2011.
13. Nicholson KM, Prieto VG, Tetzlaff MT. Bi-clonal, multifocal primary cutaneous marginal zone B cell lymphoma. *Journal of Cutaneous Pathology* 39(1):191a, 1/2012.
14. Curry JL, McQuitty E, Tetzlaff MT, Prieto VG, Duvic M, Torres-Cabala CA. CD8-positive CD30-positive lymphomatoid papulosis and its differential diagnosis: a review of 20 cases. *The Journal of Cutaneous Pathology* 39(1):99a, 1/2012.
15. Hardin J, McLemore MS, Tetzlaff MT, Prieto VG. Metastatic melanoma with multiple patterns mimicking intradermal nevus and traumatic neuroma: a possible diagnostic pitfall. *The Journal of Cutaneous Pathology* 39(1):117a, 1/2012.
16. Chu VH, Tetzlaff MT, Prieto VG, Torres-Cabala C, Bassett R, McLemore MS, Ivan D, Wang WL, Curry JA. Implications of the 2009 AJCC Melanoma Staging and Classification System for Thin Melanomas. *Modern Pathology* 25(2):117A-118A (#97), 2/2012.
17. Tetzlaff MT, Liu S, Liu A, Liegl-Atzwanger B, Xu X. Loss of microRNA-205 Expression is Associated with Melanoma Progression. *Modern Pathology* 25(2):187 (#103), 2/2012.

18. Rose CL, Curry JL, Torres-Cabala CA, Chakravarti N, Prieto VG, Tetzlaff MT. The Utility of ATF3 in Cutaneous Epithelial Neoplasms. *Modern Pathology* 25(2):132A (#109), 2/2012.
19. Duvic M, Tetzlaff MT, Clos AL, Gangar P, Talpur R. Results of a Phase II Trial of Brentuximab Vedotin (SGN-35) for CD30+ Cutaneous T-cell Lymphomas and Lymphoproliferative Disorders. *Blood* 120(21), 11/2012.
20. Milless TL, Carr R, Tetzlaff MT, Prieto VG, and McLemore MS. An Unusual Case of Extranodal Natural Killer/T-Cell Lymphoma, Nasal-Type, with Clonal T-Cell Receptor Gamma Chain Gene Rearrangement Presenting as a Rash in an Adult Caucasian Male. *Journal of Cutaneous Pathology*. 40(1):130A, 1/2013.
21. Curry JL, Chu V, Torres-Cabala CA, Tetzlaff MT, Prieto VG. Final Tumor Stage and Sentinel Lymph Node Status on Initial Biopsies of Thin Melanomas Transected at the Base. *Journal of Cutaneous Pathology* 40(1):85a-86a, 1/2013.
22. Milless TL, Wang, WL, Prieto VG, McLemore MS, Curry JL, Ivan DS, Tetzlaff MT, Torres-Cabala CA. The Impact of T-cell Receptor Gene Rearrangement by PCR in Mycosis Fungoides. *Journal of Cutaneous Pathology* 40(1):131a, 1/2013.
23. Milless TL, Curry JL, Ivan DS, Wang WL, Torres-Cabala CA, Bassett RL, McLemore MS, Prieto VG, and Tetzlaff MT. Diagnosing Ambiguous Melanocytic Tumors In A Tertiary Referral Center: The Contribution Of Fluorescence In Situ Hybridization (FISH) To Conventional Histopathologic And Immunophenotypic Analyses. *Modern Pathology* 26(2), 2/2013.
24. Kapil JP, Chakravarti N, Curry JL, Prieto VG, Wang WL, Tetzlaff MT, Torres-Cabala CA. Evaluation of Fumarate Hydratase and Hypoxia-Associated Proteins in HLRCC Syndrome and Sporadic Cutaneous Leiomyomas. *Modern Pathology* 26(2), 2/2013.
25. Tetzlaff MT, Curry JL, Ivan D, Wang WL, Torres-Cabala CA, Bassett RL, Valencia KM, McLemore MS, and Prieto VG. Immunodetection Of Phosphohistone H3 (PHH3) As A Surrogate Of Mitotic Figure Count And Clinical Outcome In Cutaneous Melanoma. *Modern Pathology* 26(2):110A, 2/2013.
26. Agarwal A, Torres-Cabala CA, Tetzlaff MT, Stockman DL, Chu V, Prieto VG, and Curry JL. The Impact on Final Breslow Thickness and Sentinel Lymph Node Status with Initial Biopsies of Cutaneous Melanomas Transected at the Base. *Modern Pathology* 26(2), 2/2013.
27. Chakravarti N, Bassett RL, Curry JL, Tetzlaff MT, Prieto VG. Differential cellular localization of activating transcription factor 3 (ATF3) in melanoma progression. *Journal of Investigative Dermatology* 133(Supplement 1):S237-S237, 5/2013.
28. Stockman D, Tetzlaff MT, Al-Zaid T, Torres-Cabala CA, Bucheit AD, Lazar AJ, Sui D, Jakob JA, Bassett RL, Prieto VG, Davies MA, Curry JL. Differential clinical associations of BRAF and NRAS mutations among histologic types of cutaneous melanomas. *Journal of Clinical Oncology* 31(15):e20034, 5/2013.
29. Litvinov IV, Tetzlaff MT, Rahme E, Gangar P, Jennings MA, Pehr K, Prieto VG, Sasseville D, Duvic, M. Identification of cutaneous T-cell lymphoma geographic hotspots in Houston metropolitan area. *Journal of Investigative Dermatology* 133(Supplement 1):S95-S95, 5/2013.

30. Litvinov I, Tetzlaff MT, Rahme E, Pehr K, Gangar P, Sasseville D, Duvic M. Geographic distribution of Cutaneous T-Cell Lymphoma cases in Houston and Texas: a comparison of the MD Anderson and Texas Cancer Registries. *Journal of Investigative Dermatology* 134:S39, 9/2013.
31. Bucheit AD, Joseph RW, Milton D, Fox P, Bassett RL, Gershenwald JE, Tetzlaff MT, Prieto VG, Lazar AJ, Davies MA. PTEN loss correlates with shorter time to brain metastasis and overall survival in stage IIIB/C melanoma patients. *European Journal of Cancer* 49(Supplement 2):S872-S873, 9/2013.
32. De la Garza Bravo MM, Curry JL, Torres-Cabala CA, Ivan DS, Drucker C, Prieto VG, Tetzlaff MT. Pigmented Extramammary Paget Disease of the Thigh Mimicking a Melanocytic Lesion: A Diagnostic Pitfall and Review of the Literature. *American Society of Dermatopathology 50th Annual Meeting*, 10/2013.
33. Duvic M, Tetzlaff MT, Clos AL, Gangar P, Talpur R. Phase II Trial Of Brentuximab Vedotin For CD30+Cutaneous T-Cell Lymphomas and Lymphoproliferative Disorders. *Blood* 122(21), 11/2013.
34. Estrella JS, Tetzlaff MT, Kazen C, Kopetz S, Maru DM, Rashid A, Hamilton SR, Broaddus RR. BRAF V600E Immunohistochemistry in Colorectal Carcinoma. *Modern Pathology* 27(2) (#706), 3/2014.
35. Stockman DL, Curry JL, Russell BR, Lazar AJ, Prieto VG, Tetzlaff MT. Clinical Next Generation Sequencing (NGS) Identifies a Subset of Melanoma Harboring SMARCB1 Mutations. *Modern Pathology* 27(2) (#1918), 3/2014.
36. Henderson SA, Tetzlaff MT, Pattanaprichakul P, Fox PS, Torres-Cabala CA, Bassett RL, Prieto VG, Richards HW, Curry JL. Immunohistochemistry for Histone H3K79me3T80ph Is Superior to PHH3 in the detection of Mitotic Chromatin and G2 Positive Nuclei in Merkel Cell Carcinoma. *Modern Pathology* 27(2) (#541), 3/2014.
37. Henderson SA, Curry JL, Torres-Cabala CA, Ivan DS, Bassett RL, Prieto VG, Tetzlaff MT. p40 Improves Diagnostic Specificity between Atypical Fibroxanthoma and Poorly Differentiated Squamous Cell Carcinoma. *Modern Pathology* 27(2) (#540), 3/2014.
38. Pattanaprichakul P, Casavilca S, Tetzlaff MT, Cano L, Sitthinamsuwan P, Barrionuevo C, Kummerdnakta S, Ramani N, Prieto VG, Curry JL, Torres-Cabala CA. Primary Acral Lentiginous Melanoma in Patients with Non-Caucasian Ethnicities from East Asia and Latin America Demonstrates Frequent Heterogenous Immunodetection of BRAFV600E and Preserved PTEN Protein Expression. *Modern Pathology* 27(2) (#563), 3/2014.
39. De la Garza Bravo MM, Patel KP, Curry JL, Torres-Cabala CA, Ivan DS, Medeiros J, Prieto VG, Duvic M, Tetzlaff MT. Shared Clonality in Distinctive Lesions of Lymphomatoid Papulosis and Mycosis Fungoides Occuring in the Same Patients Suggests a Common Origin. *Modern Pathology* 27(2) (#533), 3/2014.
40. Loghavi S, Torres-Cabala CA, Curry JL, Ivan D, Basset R, Prieto VG, Tetzlaff MT. Tumor Size Correlates with Survival in Melanomas Associated with Conventional or Cellular Blue Nevi or Displaying Blue Nevus-Like Features (So Called Malignant Blue Nevus). *Modern Pathology* 27(2) (#550), 3/2014.
41. Litvinov IV, Tetzlaff MT, Rahme E, Gangar P, Jennings MA, Pehr K, Prieto VG, Sasseville D, Duvic, M. Hotspots of CTCL cases in Houston and Texas: A comparison of the MD

- Anderson and Texas cancer registries. *The Journal of Investigative Dermatology* 134:S52, 5/2014.
42. Tetzlaff MT, Curry JL, Manyam G, Wani K, Yin V, Aldape K, Prieto V, Esmaeli B. Differentially Expressed miRNAs Implicate Pathways in Sebaceous Carcinomas and Adenomas. *Modern Pathology* 28(Supplement 2):463A-464A, 2/2015.
 43. Gonzalez-Berjon J, Tetzlaff MT, Yao J, Loose D, Broaddus R, Estrella JS. MicroRNA Associated With Outcome in Pancreatic Neuroendocrine Tumors. *Modern Pathology* 28(Supplement 2):442A-443A, 2/2015.
 44. Feldmeyer L, Fox P, Tetzlaff MT, Curry JL, Nagarajan P, Ivan D, Torres-Cabala C, Prieto VG, Aung PP. Prognostic Significance of Lymphovascular Invasion Detected By immunostaining With D2-40 and D2-40/MITF1 in Patients With Cutaneous Melanoma. *Modern Pathology* 28(Supplement 2):120A, 2/2015.
 45. Al-Rohil R, Curry JL, Torres-Cabala CA, Ivan D, Bassett R, Prieto V, Tetzlaff MT. The Contribution of Second Generation Fluorescence In Situ Hybridization (FISH) To histopathologic and Immunophenotypic Analyses in the Diagnosis of Ambiguous Melanocytic Tumors (AMT). *Modern Pathology* 28(Supplement 2):495A, 2/2015.
 46. Danialan R, Mutyambizi K, Curry JL, Torres-Cabala CA, Ivan D, Nagarajan P, Aung P, Prieto V, Tetzlaff MT. The Impact of Second-Opinion Dermatopathology Review on Melanoma Management and Stage at a Tertiary Cancer Referral Center. *Modern Pathology* 28(Supplement 2):498A, 2/2015.
 47. Tetzlaff MT, Pattanaprichakul P, Wargo J, Fox P, Patel K, Estrella J, Broaddus R, Davies MA, Routbort M, Lazar AJ, Prieto VG, Hwu WJ, Gershenwald J, Woodman S, Torres-Cabala C, Curry JL. Utility of BRAFV600E Immunohistochemistry (IHC) Expression Pattern as a Surrogate of BRAFV600 Mutation Status in 154 Patients With Advanced Stage Melanoma. *Laboratory Investigation* 95(Supplement 1):126A, 2/2015.
 48. Mudaliar K, Torres-Cabala C, Tetzlaff MT, Duvic M, Ciurea A, Hymes S, Tsai K, Prieto V, Curry JL. Vemurafenib Associated Melanocytic Lesions Lack BRAFV600E Mutation and Show Preserved BAP1 Expression. *Modern Pathology* 28(Supplement 2):125A, 2/2015.
 49. Roszik J, Joon A, Siroy A, Haydu LE, Stingo F, Baladandayuthapani V, Hwu P, Tetzlaff MT, Wargo JA, Chen JQ, Radvanyi LG, Bernatchez C, Gershenwald JE, Lazar AJF, Davies MA, Woodman SE. A novel algorithm applicable to cancer next-generation sequencing panels to predict total tumor mutation load and correlation with clinical outcomes in melanoma. *J Clin Oncol* 33(15):e9071, 5/2015.
 50. Haydu LE, Calderone TL, Miller J, Bassett RL, Joon A, Zhang JH, Morgan MB, Shaw KR, Cooper ZA, Burton EM, Siroy A, Wani KM, Stingo F, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Lazar AJF, Davies MA, and Gershenwald JE. Comparison of DNA and RNA analyte extraction and melanin removal methods from formalin-fixed, paraffin-embedded (FFPE) melanoma. *J Clin Oncol* 33(15):e20002, 5/2015.
 51. Davies MA, Joon A, Bassett RL, Roszik J, Siroy A, Haydu LE, Chen K, Stingo F, Baladandayuthapani V, Shaw KR, Meric-Bernstam F, Tetzlaff MT, Gershenwald JE, Woodman SE, Lazar AJF. Demographics, tumor characteristics, and clinical outcomes associated with somatic mutations in 201 cancer-related genes in advanced melanoma patients (pts). *J Clin Oncol* 33(15):e9057, 5/2015.

52. Litvinov I, Tetzlaff MT, Habel Y, Rahme E, Risser D, Gangar P, Jennings MA, Pehr K, Prieto VG, Sasseville D, Duvic M. Geographic distribution of cutaneous T-cell lymphoma (CTCL) cases in Houston and Texas: A comparison of the MD Anderson and Texas Cancer Registries. *Journal of the American Academy of Dermatology* 72(5):AB 159 (Abstract 728), 5/2015.
53. Kash N, Aneja S, Tetzlaff MT, Duvic M. Granulomatous mycosis fungoides in solid organ transplant recipients. *Journal of the American Academy of Dermatology* 72(5):AB160 (Abstract 1156), 5/2015.
54. McQuade JL, Chen G, Panka DJ, Reuben A, Bassett RL, Joon A, Lazar AJF, Tetzlaff MT, Simpson L, Mouton R, Patel SP, Glitza IC, Hwu WJ, Amaria RN, Diab A, Hwu P, Wargo JA, Sullivan RJ, Kim K, Davies MA. Phase II study of dabrafenib and trametinib following progression on BRAF inhibitor monotherapy in metastatic melanoma: Exploration of clinical and molecular predictors of response. *J Clin Oncol* 33(15):e20051, 5/2015.
55. Amaria RN, Wargo JA, Cooper ZA, Tetzlaff MT, Reuben A, Davies MA, Gershenwald JE, Jiang H, Austin-Breneman J, Lee JE, Hwu P, Hwu WJ, Cormier JN, Royal RE, Lucci A, Patel SP, Diab A, Glitza IC, Burton EM, Ross MI. Treatment with neoadjuvant BRAF Inhibition Yields Responses in Patients (pts) with High Risk Borderline Resectable Stage III Melanoma. *J Clin Oncol* 33(13):e20097, 5/2015.
56. Sweeney SA, Tetzlaff MT, Hymes SR. Widespread scar-like skin lesions as the initial presentation of cGVHD. *Journal of the American Academy of Dermatology* 72(5):AB154 (Abstract 895), 5/2015.
57. Cooper ZA, Reuben A, Spencer C, Austin-Breneman J, Jiang H, Chen PL, Haymaker C, Amaria RN, Tetzlaff MT, Flaherty KT, Chin L, Dwyer KC, Wargo, JA. Understanding responses to targeted therapy and immunotherapy in melanoma: Rationale for combination strategies. *INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE* 36(Supplement 1):S104 (Abstract 499), 8/2015.
58. Siroy AE, Tetzlaff MT, Davies MA, and Lazar AJ. Clonal PTEN Loss in BRAF V600-mutated Melanomas. *J Cutan Pathol*, 2015.
59. Al-Rohil RA, Torres Cabala CA, Curry JL, Duvic M, Medeiros LJ, Prieto VG, and Tetzlaff MT. Extranodal NK/T-cell lymphoma: Don't forget to cross your Ts. *J Cutan Pathol*, 2015.
60. Danialan R, Tetzlaff MT, Prieto VG, Aung PP. Melanoma Coexisting with Solar Elastosis - A Potential Pitfall in the Differential Diagnosis Between Benign Nevus and Melanoma. *J Cutan Pathol*, 2015.
61. Siroy AE, Torres-Cabala CA, Tetzlaff MT, Nagarajan P, Milton DR, Curry JL, Prieto VG, Aung PP. Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma. *Modern Pathology*. In Press.
62. Minca EC, Al-Rohil R, Wang M, Ko J, Prieto VG, Tetzlaff MT, Billings SD, and Andea A. Comparison between myPath-Melanoma gene expression score and fluorescence in situ hybridization on an extended series of melanocytic lesions. *Modern Pathology*. In Press.
63. Holmes MP, Bell D, Singh R, Luthra R, Broaddus RB, Tetzlaff MT, Esmaeli B. Conjunctival melanomas harbor BRAF mutations: Confirmatory whole exome sequencing analysis of 409 cancer-related genes. *Modern Pathology*. In Press.

64. Wimmer DA, Tetzlaff MT, Torres-Cabala CA, Milton DR, Nagarajan P, Aung PP, Prieto VG, and Curry JL. Immunodetection of mitotic figures and G2+ tumor nuclei with histone markers in Stage III Melanoma samples. *Modern Pathology*. In Press.
65. Al-Rohil RN, Feldmeyer L, Nagarajan P, Lyons GR, Curry JL, Torres-Cabala CA, Ivan D, Bassett RL, Prieto VG, Tetzlaff MT, and Aung PP. Intratumoral lymphovascular invasion detected by D2-40 correlates with metastasis in primary cutaneous merkel cell carcinoma. *Modern Pathology*. In Press.
66. Nagarajan P, Curry JL, Ning J, Piao J, Aung PP, Ivan D, Torres-Cabala CA, Prieto VG, Malipica A, and Tetzlaff MT. Melanomas of the vulva: A retrospective analysis of clinical and histopathologic parameters in 100 patients. *Modern Pathology*. In Press.
67. Petaccia de Macedo M, Haydu LE, Calderone TL, Wani K, Duncan S, Tetzlaff MT, Prieto VG, Davies MA, Gershenwald JE, and Lazar AJ. Predicting DNA Yield by calculation of extracted tissue area: Combining Digital and Molecular Pathology to empower genetic testing. *Modern Pathology*. In Press.
68. Aung PP, Ravishankar S, Friedman K, Milton D, Curry JL, Torres-Cabala CA, Ivan D, Tetzlaff MT, Gershenwald JE, Prieto VG, Nagarajan P. Prognostic significance of regression in patients with thin primary cutaneous melanoma. *Modern Pathology*. In Press.
69. Tetzlaff MT, Feldmeyer L, Hudgens C, Lyons GR, Bassett RI, Curry JL, Torres-Cabala CA, Wargo JA, Prieto VG. The composition, density and location of immune infiltrates correlate with survival in merkel cell carcinoma. *Modern Pathology*. In Press.
70. Tetzlaff MT, Singh R, Seviour EG, Curry JL, Bell D, Broaddus RB, Ram P, Prieto VG, Luthra R, Esmali B. Whole exome sequencing of 409 cancer associated genes demonstrates frequent clinically actionable mutations in sebaceous carcinoma. *Modern Pathology*. In Press.